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4. ABSTRACT 
Diffuse large B cell lymphoma (DLBCL) and plasmablastic lymphoma (PBL) represent 
aggressive non-Hodgkin’s large cell lymphomas, particularly in the setting of HIV infection.  
Due to significant clinical, morphologic, immunophenotypic and molecular heterogeneity, 
remissions may be achieved in only 40% of DLBCL, despite multidrug chemotherapeutic 
regimens.  Since the introduction of highly active antiretroviral therapy (HAART), recent 
studies have documented improved survival outcome in patients with AIDS-related 
lymphomas.  
Aims: The study aimed to contribute a South African perspective by correlating the HIV 
status and prognosis of DLBCL and PBL with differentiation profiles assessed by 
immunophenotyping.  
Methods: A prospective study was conducted, based on the morphologic, 
immunophenotypic and clinicopathologic analysis of 61 cases of large cell lymphomas, 
comprising 52 DLBCL and 9 de novo PBL.  All cases were diagnosed between January 
2004 and December 2007 in the histopathology department, division of Anatomical 
Pathology, National Health Laboratory Service, Groote Schuur hospital, Cape Town, South 
Africa.  
Results: The overall survival of patients with PBL was significantly poorer than that of 
DLBCL (log-rank p value 0.002).  Despite HAART, the overall survival of patients with 
DLBCL associated with HIV infection was poorer than DLBCL occurring in HIV negative 
patients (p value < 0.0001).  In the HIV positive group, profound immunosuppression was 
evident as the mean CD4 count at the time of lymphoma diagnosis was 151cells/mm3 in 
patients with DLBCL and 61cells/mm3 in patients with PBL.  In addition, HIV positive patients 
were found to be of significantly younger age at presentation with greater likelihood of 
extranodal lymphoma relative to HIV negative patients.  When the International Prognostic 
Index (IPI) was assessed, the overall survival of patients with low to intermediate risk IPI 
scores (0-2) was better than those with intermediate to high risk IPI scores (3-5).  However, 
this difference was not statistically significant (p value 0.794).  When Hans’ algorithm was 
used to prognostically stratify DLBCL, the overall survival of patients with germinal center-
subtype DLBCL was better than that of non-germinal center subtypes.  However, the 
difference in survival was not statistically significant (p value was 0.188).  Similarly, when 
Muris’ algorithm was used to stratify subtypes of DLBCL, the overall survival of patients with 
group 1-type DLBCL was better than that of group 2-type DLBCL.  However, once again, no 
statistical significance was demonstrated (p value was 0.399).  No statistical significance 
was found when Bcl-2 expression was assessed independently of the IPI score, CD10, Bcl-6 
and MUM1 expression (p value 0.371).  However, when Bcl-2 expression occurred in 
germinal center-type DLBCL, using Hans’ algorithmic stratification, improved survival was 
conferred by the germinal center phenotype (p value 0.007).   
Conclusion:  The study confirmed that diffuse large B cell lymphoma and plasmablastic 
lymphoma are high-grade tumours with significant potential for aggressive behaviour and 
poor outcome in the setting of profound immunosuppression due to HIV infection.   Recent 
amendment of the South African National Antiretroviral Treatment Guidelines has created 
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the potential for improved survival in patients with AIDS-related malignancies.  Further 
studies are required to assess the effect of these amendments, in combination with the role 
of targeted-immunotherapy (Rituximab) on survival, in patients with AIDS-related non-
Hodgkin’s lymphomas.  
 
5. REVIEW OF THE LITERATURE 
5.1 A concise history of lymphoma classifications, focusing on the 
evolution of diffuse large B cell lymphoma and plasmablastic lymphoma.   
In 1832, the first form of lymphoma was described by Thomas Hodgkin which later 
became well known as Hodgkin’s lymphoma.  Characteristic neoplastic binucleate or  
multinucleate cells were independently described by Carl Sternberg and Dorothy  
Reed in 1898 and 1902, respectively.  These cells became known as Reed-
Sternberg cells. 1 
Several decades later, in 1963 Robert J Lukes proposed the first classification for 
Hodgkin’s lymphoma. Other forms of lymphoma were subsequently recognised and 
described, constituting a large group of different cancers requiring further 
classification.  In 1956, Henry Rappaport proposed the Rappaport classification 
(Table 1) which became the first widely used and accepted classification of 
lymphomas other than Hodgkin’s lymphoma.  The classification was submitted for 
publication as a fascicle of the Armed Forces Institute of Pathology in 1959 and was 
published in 1966.  This classification emphasised the architecture and patterns of 
lymphomas , specifically nodular and diffuse subtypes of each cytological form, other 
than Hodgkin’s lymphoma.  Although the Rappaport classification lacked precision in 
terminology and lineage, it was found to be clinically and prognostically useful.  As 
such, this classification persisted for nearly twenty years. 2,3 
 
In 1974, the immunologically orientated Lukes and Collins classification (Table 2) 
introduced new terminology such as follicle center cell, cleaved and non-cleaved. 
The classification was based on cell lineages and morphological alterations 
associated with the suggestion that antigenic stimuli induced lymphocyte 
transformation.  2-4 
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                      Malignant lymphoma 
      Nodular                                  Diffuse 
1. Lymphocytic type, well differentiated 
2. Lymphocytic type, poorly differentiated 
3. Mixed type (lymphocytic and reticulum cell) 
4. Reticulum cell type 
5. Hodgkin’s  
 
 
 Table 1: Original Rappaport classification of 1956  2,3 
 
  B cell types 
   Small lymphocyte (chronic lymphocytic leukaemia; CLL) 
   Plasmacytoid lymphocyte 
   Follicular center cell (FCC) types (follicular, diffuse and sclerotic) 
     Small cleaved 
     Large cleaved 
     Small non-cleaved 
     Large non-cleaved 
    Immunoblastic sarcoma (of B cells) 
 
 Table 2: Original Lukes and Collins classification of 1974 (B cell types) 2,3 
 
In 1974, the Kiel classification (Table 3) was formulated by Karl Lennert and 
members of the European Lymphoma Club.  The central tenet of this classification 
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was that the cytology of lymphoma cells could be used as a grading system to 
predict clinical behavior.  In addition, the nodular lymphomas proposed by Rappaport 
were considered the neoplastic equivalent of germinal center B cells. New 
terminology for follicle center B cells was proposed as follows: 
    1) Germinoblasts / Large non cleaved cells / Centroblasts 
    2) Germinocytes / Small cleaved cells / Centrocytes 
 
 
Low-grade malignancy 
      Malignant lymphoma – lymphocytic (CLL and others) 
      Malignant lymphoma – lymphoplasmacytoid  (immunocytic) 
      Malignant lymphoma – centrocytic 
      Malignant lymphoma – centroblastic-centrocytic-follicular; 
                                            follicular and diffuse; diffuse; with 
                                            and without sclerosis 
      High grade malignancy 
      Malignant lymphoma – centroblastic 
      Malignant lymphoma – lymphoblastic 
          Burkitt type 
          Convoluted-cell type 
          Others 
    Malignant lymphoma - immunoblastic  
 
 
Table 3:  Original Kiel classification of 1974  5 
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During the 1960’s and 1970’s the existence of several distinct lymphocyte lineages 
(T, B, and NK) was established.  It was accepted that it was not possible to reliably 
predict the lineage by morphologic assessment alone. 5, 6, 7  
Lymphoid cells were found to have surface antigens or receptors which could 
allow for identification of the lineage of both normal and neoplastic cells. 8, 9 
These observations led to the recognition that lymphomas were tumours of the 
immune system.  
 
In the 1970’s four additional classification systems were also in use:  
The Dorfman classification, World Health Organisation (WHO), the Updated 
Rappaport classification and the British National Lymphoma Investigation 
classification.  
The various classifications contained different terminology and different criteria for 
diagnosis which resulted in confusion and diagnostic difficulty.   
Subsequently, in 1982, the Working Formulation (Table 4a) was published by the 
National Cancer Institute sponsored Lymphoma Classification Project.  It was 
essentially based on concepts and terms of the Rappaport, Lukes-Collins and Kiel 
classifications. 10  It encompassed reproducible morphologic appearances which 
included architectural and cytological features as well as the neoplastic cell size. The 
term non-Hodgkin’s lymphoma (NHL) was created and three grades of lymphoma 
(Table 4b) were clinically defined as low, intermediate and high grade.  The Working 
Formulation became the standard classification for this group of lymphomas. 
However, this classification was criticised as being biologically imprecise.  11     
In 1988, Stansfield and colleagues proposed the updated/revised Kiel classification 
(Table 5) introducing clear delineation of B & T cell lymphoma entities. Intended for 
nodal lymphomas, little attention was given to extranodal disease. This classification 
was criticised for its complexity. It was also found to lack clinical relevance and was 
considered poorly reproducible.    2, 9, 11   
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 Malignant Lymphoma, small lymphocytic (chronic lymphocytic      
leukaemia) 
 Malignant Lymphoma, follicular, predominantly small cleaved cell  
 Malignant Lymphoma, follicular, mixed (small cleaved and large   
cell)  
 Malignant Lymphoma, follicular, predominantly large cell  
 Malignant Lymphoma, diffuse, small cleaved cells  
 Malignant Lymphoma, diffuse, mixed (small and large cells)  
 Malignant Lymphoma, diffuse large cells  
 Malignant Lymphoma, large cell, immunoblastic  
 Malignant Lymphoma, lymphoblastic  
 Malignant Lymphoma, small non-cleaved cells (Burkitt's lymphoma)  
 Composite  
 Mycosis fungoides  
 Histiocytic  
 Extramedullary plasmacytoma  
 Unclassifiable  
Table 4(a):   Working Formulation 10 
 
 
 
         Low Grade                       Intermediate Grade                     High Grade 
 
Small lymphocytic                     Follicular large cell                          Large cell immunoblastic 
Follicular small-cleaved cell      Diffuse small cleaved cell                Lymphoblastic 
Follicular mixed small-cleaved  Diffuse mixed small and large cell  Small non-cleaved  
                                                                                                             (Burkitt's/ non-Burkitt's)                                 
 
Table 4(b):   Working Formulation – lymphoma grades 10 
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Table 5 Updated Kiel classification – B cell non-Hodgkin’s lymphoma 3,11  
  
 
The divergent use of lymphoma terminology in the United States and Europe lead to 
difficulties in interpretation of the clinical and haematopathology literature.   
Subsequent attempts to identify distinct lymphoma entities with the aim of creating 
diagnostic reproducibility and acceptable terminology were spearheaded by the 
International Lymphoma Study Group (ILSG) which comprised 19 expert 
haematopathologists.  All the available information which included clinical features, 
morphology, immunophenotype and genetic characteristics were used to define the 
different types of lymphoid tumours. 11, 14  
In 1994, the Revised European American Lymphoma (REAL) Classification was 
established and comprised a list of lymphoid neoplasms considered to be distinctive 
biological entities which could be reproducibly diagnosed. The REAL classification 
delineated precursor and peripheral lymphoid neoplasms of both B & T cell lineages.  
It included Hodgkin’s disease & plasmacytoma/multiple myeloma. This classification 
was applicable to nodal and extranodal lymphomas. 12  
However, the REAL classification was criticised because it was not tested for clinical 
and prognostic value.  In addition, at the time of introduction there was no data as to 
B cell 
Low grade 
  Lymphocytic-chronic lymphocytic and prolymphocytic leukaemia      
  Hairy cell leukaemia 
  Lymphoplasmacytic/cytoid 
  Plasmacytic 
  Centroblastic/centrocytic 
  Centrocytic 
High grade 
 Centroblastic 
 Immunoblastic 
 Large cell anaplastic 
 Burkitt’s lymphoma 
 Lymphoblastic 
 Rare types 
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how well it could be applied by haematopathologists. These issues were 
subsequently addressed in the Lymphoma Classification Project. 
The Lymphoma Classification Project addressed several salient issues regarding 
lymphoma classifications by comparing the applicability of the REAL classification 
with the Working Formulation and Kiel Classification.  The Lymphoma Classification 
Project established that the REAL classification could be applied with a significant 
degree of accuracy, reproducibility and prognostic significance.  It was found that 
over 95% of the lymphoma cases with adequate material could be optimally 
classified.  The REAL classification was found to have an interobserver concordance 
of 85% for major subtypes and an intraobserver concordance of 94%.  Overall, the 
REAL classification was found to be a good predictor of survival.  In addition, 
immunophenotyping was found to be an essential tool for classification of most 
lymphomas.  In terms of the incidence of non-Hodgkin’s  lymphoma, diffuse large B 
cell lymphoma was found to be the commonest lymphoma, followed by follicular 
lymphoma.  The category of diffuse large B cell lymphoma was created by the REAL 
classification which included cleaved or non-cleaved and immunoblastic lymphoma 
from the Working Formulation.  It also incorporated centroblastic diffuse and 
immunoblastic B-cell type from the Kiel classification. 
The study established an indisputable fact that classification alone was not the only 
predictor of clinical outcome.  It further contributed that patients could be stratified 
into prognostically significant groups according to the International Prognostic Index 
(IPI).  13, 14  The updated REAL Classification and the data generated by the 
Lymphoma Classification project have been of great value in formulating the World 
Health Organisation classification of haematopoietic neoplasms.   The most recent 
WHO classification of 2008 acknowledges the presence of several subtypes of 
diffuse large B cell lymphoma (DLBCL).  These include T cell/histiocyte rich large B-
cell lymphoma, CD5-positive DLBCL, primary DLBCL of the CNS, primary cutaneous 
DLBCL- leg type, EBV-positive DLBCL of the elderly and DLBCL associated with 
chronic inflammation.  Although plasmablastic lymphoma was initially considered to 
be a variant of DLBCL, it is now recognised as an independent diagnostic entity. 15, 55  
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5.2 Diffuse large B-cell lymphomas in relation to B-lymphocyte   
differentiation  
B-cell neoplasms are inclined to mimic stages of normal B-cell differentiation. 
At the outset of B-cell differentiation within bone marrow precursors, the  
immunoglobulin (Ig) heavy (H) chain variable region is formed by an ordered process  
of immunoglobulin gene rearrangement resulting in the assembly of distinct variable 
(V), diversity (D) and joining (J) gene segments. This process is known as VDJ  
recombination. 16 
Once a functional non-autoreactive antigen receptor is generated, progenitor B-cells  
and/or B lymphoblasts undergo immunoglobulin gene  rearrangements and  
differentiate into surface immunoglobulin positive (IgM+ IgD+) naïve B cells which  
are released into the peripheral B-cell pool. 17  
 When an antigen is encountered, the antibody expressed by a naïve B cell may be  
modified by class-switch recombination and somatic hypermutation, the latter is  
restricted to B cells proliferating within the environment of the germinal centre.   
Somatically mutated V-region genes are a hallmark of germinal center B cells and 
their descendants. 18 
The naïve B-cell enters the primary follicle, forming a germinal center (GC), wherein 
it matures to a CD10 and Bcl-6 expressing centroblast.  At the time of transit through 
the germinal center, B-cells undergo somatically acquired mutations of IgV (heavy 
and light chain variable region genes) as well as mutations of the BCL-6 gene.   
Bcl-6 is a DNA-binding zinc-finger transcriptional regulator which is required for  
germinal center formation.  Non-neoplastic germinal center centroblasts do not 
express Bcl-2 protein. 19, 23 
Within the light zone of the germinal centre, the centroblast matures to a centrocyte  
which re-expresses Bcl-2 protein. Down regulation of Bcl-6 expression follows 
interaction with the CD23 and CD40 ligand on follicular dendritic cells and T-cells.   
 
IRF4/MUM1 expression occurs in late centrocytic stages and in plasma cells.  Within  
the germinal center, downregulation of Bcl-6, partly by the action of the IRF4/MUM1  
protein, is essential for the differentiation of B lymphocytes to plasma cells or  
memory B-cells. Within the non-neoplastic germinal center B lymphocyte, expression  
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of IRF4/MUM1 and Bcl-6 are mutually exclusive. 20   
 
Histogenetic subdivision of B-cell lymphomas occurs as follows:    
 
(1) Lymphomas derived from pre-germinal center B-cells lacking somatic     
hypermutation of IgV and BCL-6 genes 
 
(2) Lymphomas closely resembling germinal center B cells associated with 
somatic IgV and/or BCL-6 hypermutation and Bcl-6 expression 
 
(3) Lymphomas representing post germinal center B cells associated with 
somatic IgV and/or BCL-6 hypermutation as well as CD138/syndecan-1 
positivity.   18, 115 
 
Bcl-6 
The BCL-6 gene, located on chromosome 3q27, encodes a zinc finger protein which  
functions as a transcriptional repressor.  Bcl-6 expression is tightly regulated during  
B cell differentiation and strong nuclear expression is evident preferentially in  
germinal center B cells. 21  While Bcl-6 and MUM1 immunoexpression are mutually 
exclusive in non neoplastic B cells, subsets of activated B cell-like DLBCL may 
express Bcl-6 in combination with MUM1/IRF4. 58, 66, 116   Approximately 30% of 
diffuse large B cell lymphomas show alterations of the BCL-6 gene at the 5' non-
coding region by 3q27 chromosomal translocations. 22  The translocations may result 
in replacement of the regulatory region of the BCL-6 gene by heterologous 
immunoglobulin (IG) genes.  This is the commonest translocation occurring in 
DLBCL.  Deregulation of the BCL-6 gene subsequently occurs as a result  
of promoter substitution, a process implicated in lymphomagenesis.  23 
 The significance of Bcl-6 expression in diffuse large B cell lymphomas will be 
discussed at length as a prognostic factor.  
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Bcl-2 
The BCL-2 gene is located on 18q21 and the gene product is an oncoprotein which  
inhibits apoptosis via the intrinsic mitochondrial pathway.  Bcl-2 oncoprotein resides 
on the cytoplasmic side of the mitochondrial outer membrane, endoplasmic reticulum 
and nuclear envelope.  In non-neoplastic lymphoid tissue, lymphocytes in the mantle 
region and T cell region display positive cytoplasmic staining.  Very few T cells within 
the germinal centers are labelled. 24 
Deregulated expression of Bcl-2 oncoprotein occurs as a result of the t(14;18) in  
which the BCL-2 gene is juxtaposed to the immunoglobulin (Ig) heavy chain locus  
(14q32).   This translocation is present in 20-30% of diffuse large B cell lymphomas  
and 85% of follicular lymphomas.  25, 26 
 
 
IRF4/MUM1 
MUM1 is an interferon regulatory transcription factor and a protein product of the 
IRF4/MUM1 gene (multiple myeloma oncogene 1) which is located on chromosome 
6p25.  IRF4 is a possible mediator of nuclear factor kB proliferative responses that is  
required for proliferation of B and T lymphocytes. 27  
The MUM1p monoclonal antibody used in this study is expressed in the late stages 
of B cell differentiation.  Positive staining occurs within the nuclei and cytoplasm of 
plasma cells/plasmablasts and “light zone” regions of the germinal center within 
centrocytes.  Approximately 75% of diffuse large B cell lymphomas strongly express 
MUM1 protein and there is often co-expression of Bcl-6, unlike mutually exclusive 
MUM1 and Bcl-6 expression which occurs in non neoplastic germinal center B cells. 
This finding is suggestive of deregulation of MUM1 and Bcl-6 proteins in diffuse large 
B cell lymphoma.  MUM1 expression may also occur in activated normal and/or 
neoplastic T lymphocytes often with co-expression of CD30. Positive staining also 
occurs in the neoplastic cells in Hodgkin’s lymphoma.  28, 29 
The translocation t(6;14)(p25;q32) described in multiple myeloma involves 
juxtaposition of the immunoglobulin heavy chain (IgH) locus to the multiple myeloma 
oncogene 1 resulting in over expression of the latter and resultant contribution to 
oncogenic activity. 29  MUM1 immunoreactivity has also been reported in   
melanoma. 30 
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CD38 
CD38 is encoded on chromosome 4 and is recognised as a transmembrane            
molecule. This molecule plays a role in the synthesis of cyclic ADP-ribose which in  
turn functions as a second messenger for glucose induced insulin secretion and  
regulates mobilisation of intracellular calcium ions. 31   Depending on the cellular  
enviroment, CD38 functions as a positive and negative regulator of cell activation  
and proliferation.  CD38 is also involved in adhesion between human lymphocytes  
and endothelial cells and is considered an activation marker.  It has been established 
that CD31 functions as the ligand for CD38. 32  CD38 been found to deliver potent 
growth and differentiation signals to lymphoid and myeloid cells.   
CD38 immunoexpression has been established in immature B and T lymphocytes 
lineages, germinal center B cells and Ig-secreting plasma cells.  
Positive staining may also occur in monocytes, NK cells, erythroid and myeloid  
progenitors.   
Diagnostic expression occurs in T-cell acute lymphoblastic lymphoma, 
chronic lymphocytic leukaemia (CLL)  / small lymphocytic lymphoma,  
atypical CLL, transformed CLL, diffuse large B cell lymphoma, follicular lymphoma,  
lymphoplasmacytic lymphoma, myeloma, plasmablastic lymphoma, plasma cell  
neoplasms and primary effusion lymphoma. 31, 38 
 
 
CD138 
CD138 (also known as syndecan-1) is a member of the syndecan family of  
transmembrane proteoglycans bearing extracellular domains composed of heparin  
sulphate and chondroitin sulphate. Reiland et al. 33 found four tyrosine and  
serine/threonine complexes which serve as phosphorylation sites within the 
transmembrane and cytoplasmic domains of CD138.  
The exact function of CD138 is unknown.  However, roles in autocrine and/or 
paracrine cytokine function have been suggested in association with delaying of 
apoptosis and increasing viability of leukaemic cells, particularly with regard to 
expression of CD138 in B-cell chronic lymphocytic leukaemia. 34 
CD138 may play a role in cellular functions such as proliferation, cell-matrix and  
cell-cell adhesion.   Mediation of adhesion of myeloma cells to type I collagen has  
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been attributed to CD138. 35 
CD138 expression has been found in the late stages of B-cell differentiation within  
immunoglobulin producing plasma cells and immunolabelling occurs in 
myeloma/plasmacytoma, B-CLL and lympoplasmacytic lymphoma. 36  Expression 
has also been established in immunoblastic variants of diffuse large B cell lymphoma 
occurring in HIV infected patients.  37 
CD138 expression has also been established in simple and stratified epithelia 
(including stratified keratinocytes), fibroblasts and endothelial cells. 38 
 
CD10 
CD10 is a metalloendopeptidase called neprilysin which is involved in the 
inactivatation of a variety of biologically active peptides.  Initially CD10 was identified  
as the common acute lymphoblastic leukaemia antigen (CALLA).  Identification of  
CD10 has been found on the surface of normal early lymphoid progenitor cells, 
immature B cells and germinal center B cells.  In lymphoid tumours, expression 
occurs on cells of lymphoblastic lymphoma/leukaemia, Burkitt’s lymphoma, follicular  
germinal center lymphomas (follicular lymphoma and diffuse large B cell lymphoma)  
and chronic myelocytic leukaemia (CML) in lymphoid blast crisis. 39, 40 
The significance of expression of CD10 in diffuse large B cell lymphomas has varied  
among different studies and will be discussed at length as a prognostic factor.  
 CD10 expression also occurs in various non-lymphoid cells, such as  
endometrial stromal cells, br ast myoepithelial cells, bile canaliculi and fibroblasts. 
High expression occurs on the brush border of kidney and gut epithelial cells. 38 
VS38C  
VS38C is a marker for plasma cells. It is directed towards proteins associated with 
the endoplasmic reticulum.  Labelling includes plasma cells and plasma cell 
neoplasms such as myeloma, plasmacytoma and plasmablastic lymphoma. Positive 
staining also occurs in lymphoplasmacytoid lymphoma.  In addition, immuno-
expression has been reported in neuroendocrine tumours and melanocytic lesions. 
p63 protein, a transmembrane antigen, is a synonym for the antigen found in both 
plasma cells and epithelium.  41, 42, 43 
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 Ki67 
The Ki67 antigen is a nuclear protein which is expressed during all active phases of 
the cell cycle.  It is not present in cells which are in the resting phase of the cell cycle 
(G0).  During interphase, there is exclusive expression within the nucleus.  
Interestingly, during mitosis most of the protein is relocated to the surface of 
chromosomes.  As the cell enters a non-proliferative state, the antigen is usually 
rapidly degraded.  There is no known expression of Ki-67 during the process of DNA 
repair.  Ki67 antigen expression occurs in normal and neoplastic cells. 44, 45, 46 
 
5.3  General features of diffuse large B cell lymphoma 
Diffuse large B cell lymphoma (DLBCL) is known to be a malignant neoplasm of 
large B lymphoid cells representing approximately 20-30% of non-Hodgkin’s 
lymphomas in Western countries and constituting greater percentages in developing 
countries.47   However, the incidence of DLBCL in Africa is at present unknown.  
DLBCL is an aggressive malignancy characterised by significant clinical, 
morphologic and molecular heterogeneity.  Despite multidrug chemotherapeutic 
regimens, remissions may be achieved in only 40% of cases. 48 
Underlying immunodeficiency is a significant risk factor for the development of 
DLBCL.  Acquired immunodeficiency syndrome (AIDS) -associated lymphomas are 
defined as those that occur with increased frequency in patients infected with Human 
immunodeficiency virus (HIV) with low CD4 counts, representing one of the 
commonest AIDS defining illnesses. 49  In the United States, Cote et al 50 
demonstrated a 165-fold increase in the relative risk of developing lymphoma within 
three years of an AIDS diagnosis compared with patients unaffected by AIDS.   
Before the availability of highly active antiretroviral therapy, all subtypes of non-
Hodgkin’s lymphoma were increased up to 200 times in patients infected with HIV.  
DLBCL represents one of the commonest HIV-associated non-Hodgkin’s 
lymphomas.  Other aggressive B-cell lymphomas included in this group are 
plasmablastic lymphoma, Burkitt’s lymphoma and primary effusion lymphoma.  51 
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5.4  Prognostic factors 
Various prognostic factors have been proposed to predict the outcome of aggressive 
non-Hodgkin’s lymphomas.  52 
 
5.4.1 International Prognostic Index 
The International Prognostic Index (IPI) is an important clinical prognostic tool which 
encompasses clinical parameters such as age (>60 years), performance status, 
advanced Ann Abor stage (III or IV), extranodal involvement and abnormal serum 
lactate dehydrogenase.  These parameters are used to stratify patients into (low, 
intermediate and high risk) prognostic groups based on the relative prognostic index. 
53, 55, 56, 58        
 
Figure 1 – International Prognostic Index and prognostic groups 
                                                                 
 
 
 
 
 
 
 
 
 
IPI score 
PROGNOSTIC 
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5.4.2  Morphologic subtypes of DLBCL 
 
At a morphological level, the definition of a large B cell is that in which the  
nuclear size is equal to or exceeds the size of a normal macrophage nucleus or 
more than twice the size of a normal lymphocyte. 47   The large B cell displays a 
mean diameter which is equal to or greater than 20um. 53 
 
The common morphologic variants of DLBCL include centroblastic, immunoblastic  
and anaplastic variants. 
 
Centroblastic variant - characterised by medium to large lymphoid cells with       
vesicular nuclei in which there are two to four nucleoli occurring in close proximity to 
the nuclear membrane. The cytoplasm may be sparse with an amphophilic to 
basophilic hue. 
 
Immunoblastic variant - characterised by greater than 90% of tumour cells 
displaying a centrally located single nucleolus and significant amount of basophilic 
cytoplasm.  
 
  Anaplastic variant of DLBCL contains large round or polygonal cells displaying  
  significant nuclear pleomorphism and bizarre cytomorphologic features. This variant 
may mimic poorly differentiated carcinomas and melanoma.   53, 54  
 
 The prognostic significance of centroblastic and immunoblastic morphologic 
 subtypes of diffuse large B cell lymphoma is controversial.  Some studies have 
demonstrated better prognostic outcome in centroblastic DLBCL compared with 
immunoblastic DLBCL.  However, the clinical significance of the morphologic 
features of the tumour, in the absence of the immunophenotype and molecular 
signature, is of doubtful significance due to interobserver variability and 
variable/mixed morphologic appearances occurring among individual cells within the 
same tumour. 54, 55   
DLBCL which occurs in HIV infected patients may also be composed of centroblasts  
and/or immunoblasts.  Approximately 25-30% of these tumours are composed of  
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centroblasts predominantly, with scattered intermixed immunoblasts. 
This morphologic appearance is similar to that occurring in the HIV-negative  
population.  Evidence of Epstein Barr virus (EBV) infection is demonstrable in 30% of  
these tumours by the use of EBER in situ hybridisation.   
The immunoblastic morphologic subtype of DLBCL exhibiting plasmacytoid features  
accounts for approximately 10% of cases occurring in HIV positive patients and is  
thought to be more characteristic of HIV infection.  EBV infection is demonstrable in  
90% of these cases by means of EBV LMP1 (latent membrane protein 1)  
immunohistochemistry, unlike the centroblastic subtype which lacks EBV LMP1  
immunoexpression. 56, 57 
 
 
5.4.3  Subdivisions of DLBCL based on immunohistochemistry and gene expression 
profiles 
 
 At immunohistochemical and molecular levels there have been several salient  
subdivisions of DLBCL.    
 
Hans et al  58 stratified 152 cases of de novo DLBCL into prognostically significant 
subgroups with germinal center B-cell–like (GCB), activated B-cell–like (ABC) and  
type 3 gene expression profiles.  This subdivision was based on tumour cell 
expression of Bcl-6, CD10 and IRF-4/MUM1 as defined by the Hans algorithm 
(Figure 2).  This study correlated the subclassification of DLBCL by gene expression 
with protein expression using immunohistochemistry.    All of the cases had 
immunohistochemistry, using tissue microarray, combined with previously evaluated 
cDNA (complementary deoxyribonucleic acid) microarray gene expression data 
using the Lymphochip cDNA microarray.  The combined analysis and interpretation 
allowed for an optimal prognostically advantageous classification of DLBCL.  The 
tumour cells were considered positive if 30% or more stained with the various 
antibodies used.  The concordance rate between immunohistochemistry and gene 
expression profiles was found to be 71% in GCB-like DLBCL and 88% in non-GCB 
DLBCL.   This fractional discordance is attributed to the interpretation of Bcl-6 
immunoexpression and associated gene expression profiles.  Although Bcl-6 is 
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primarily a germinal center marker, when Bcl-6 expression occurred in combination 
with MUM1 expression, the tumour was found to have an ABC gene expression 
pattern which was associated with inferior survival outcome.  This finding would 
account for discrepancies in outcome prediction of DLBCL when Bcl-6 expression is 
assessed in isolation of MUM1 expression and gene expression profiles.  
 
Figure 2 – Hans’ algorithmic stratification of DLBCL  58 
 
 
 
 
Alizadeh et al. 116   used DNA microarrays to characterise varying gene expression 
profiles in DLBCL which allowed for subdivision into germinal center-like diffuse large 
B cell lymphoma (GC-DLBCL) and activated B cell-like DLBCL (ABC-DLBCL).  
Congruent with the findings by Hans et al. 58 the GC-DLBCL was found to be 
associated with favourable outcome.   
In a retrospective study of 42 cases of de novo DLBCL by Chang et al. 59 similar 
findings were established in that DLBCL with immunophenotypic expression patterns 
of GC B-cells had improved overall survival relative to those with expression patterns 
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of activated B cells.  In this study Bcl-6, CD10, MUM1 and CD138 were assessed 
with cut-off levels for positive staining set at 20%.  
The cases were divided into three patterns of immunohistochemical expression: 
 Pattern A –  
    GC B-cell pattern expressing CD10 and/or Bcl-6 but not activation markers   
Pattern B –  
    activated GC B-cell pattern expressing at least one GC B-cell marker and  
    one activation marker 
 Pattern C –  
   activated non-GC B-cell pattern expressing MUM1/IRF4 and/or CD138     
   but not GC B-cell markers.  
 
Similar to the activated germinal center B-cell (pattern B) subdivision of DLBCL by 
Chang et al, 59 Madan et al. 60 found that the immunophenotype in AIDS-related 
DLBCL was intermediate between the germinal center and activated B-cell types 
with frequent co-expression of both germinal center cell antigens (CD10 and Bcl-6) 
and post-GC cell marker (MUM1).  
Carbone et al. 61 divided AIDS-related DLBCL into two categories. The first included 
the LMP1 negative, CD138 negative and Bcl-6 positive phenotype, which 
corresponded to the centroblastic subtype of DLBCL.  The LMP-1 positive, CD138 
positive and Bcl-6 negative phenotype corresponded to the immunoblastic subtype 
of DLBCL.   
It is noteworthy that in one of few studies to emerge from Africa, specifically Uganda, 
Tumwine et al. 62  established that the activated germinal center-type DLBCL, 
defined as those expressing CD10, Bcl-6, MUM1 and CD138, was found to have the 
best prognosis relative to other groups of DLBCL in their study.  
Using tissue microarrays constructed from 81 cases of DLBCL, Amen et al. 63 
defined the germinal center-subgroup (GC) of DLBCL as that which expressed Bcl-6 
or CD10 irrespective of MUM1expression.  The GC subgroup was subsequently 
subdivided into a favourable germinal center subset on the basis of absence of 
expression of both Bcl-2 and cyclin D2 and an unfavourable germinal centre subset 
which was positive for either Bcl-2 or cyclin D2 (Figure 3).  The absence of both Bcl-6 
and CD10 expression defined a non-germinal center subset of DLBCL.  
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In this study Bcl-6, CD10, Bcl-2 and MUM1 were considered positive if there was 
 moderate to strong positivity in 30% of tumour cells.  When assessing cyclin-D2,  
10% of cells having moderate to strong staining were considered positive.  
Significantly improved event free survival and overall survival were found in the  
absence of cyclin D2 and Bcl-2 expression. Thus the favourable germinal  
center subset was defined.  A difference is apparent in the definition of germinal-
center subgroups by Hans et al.58 and Amen et al.63   The former group would 
classify CD10, Bcl-6 and MUM1 positive DLBCL as GCB subtype due to the 
presence of concomitant GC gene expression profiles found in similar tumours in 
their study.  In contrast, CD10 negative, Bcl-6 positive and MUM1 positive cases 
would be classified as non-GC subtype of DLBCL due to the likelihood of an 
associated ABC gene expression profile.  However, both Bcl-6 and CD10 are well-
recognised germinal center markers.  Therefore, the latter group of investigators 
feasibly allowed for further stratification by employing the use of cyclin D2 and Bcl-2 
to successfully create favourable and unfavourable GC subgroups. 
 
Figure 3 -  Amen’s algorithmic subdivision of DLBCL  63 
 
 
 
The prognostic significance of Bcl-6 expression was reiterated by Lossos et al. 64 in 
that Bcl-6 expression was found to be the single most important factor which was 
predictive of good prognosis among patients with DLBCL.  In diffuse large B cell 
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lymphoma, BCL-6 gene rearrangement correlates strongly with improved survival 
outcome.  By employing the use of 63 cases of primary DLBCL, Lossos et al.64  
investigated BCL-6 m-RNA gene expression by real-time quantitative reverse 
transcription polymerase chain reaction (RT-PCR) analysis and Bcl-6 protein 
expression by immunohistochemistry.  This study established that BCL-6 mRNA 
gene expression and Bcl-6 protein expression were associated with significantly 
better overall survival.    
 Furthermore, Winter et al. 65  suggested the presence of therapeutic significance 
when Bcl-6 expression occurred in DLBCL.  Importantly, this group established that 
patients with Bcl-6-negative DLBCL had a survival advantage when Rituximab was 
added to the CHOP treatment protocol. This survival advantage was not seen in 
cases of Bcl-6-positive DLBCL.  
 
Muris et al. 66 established an interesting algorithmic stratification of cases of primary 
nodal DLBCL into prognostically favourable (group 1) and unfavourable groups 
(group 2) based on assessment of tumour expression of Bcl-2, MUM1 and CD10 
(Figure 4).  Using 71 cases of primary nodal DLBCL, this algorithmic stratification 
was found to be most predictive of clinical outcome in patients with intermediate to 
high IPI scores.  In this study, the CD10 expression appeared to be more indicative 
of germinal-center phenotype than combined CD10 and Bcl-6 expression. This is 
due to the finding that Bcl-6 expression also occurred frequently in DLBCL cases 
expressing MUM1 in keeping with an activated B-cell phenotype.  Based on 
statistical analysis, the optimal cut-off point (the threshold with the most 
discriminative power) was found to be at 30% for CD10, Bcl-6 and MUM1.  The 
optimal cut-off for Bcl-2 was found to be 50% positivity within tumour cells.  MUM1 
expression correlated with Bcl-2 expression in terms of poor outcome. It was 
interesting to note that when both Bcl-2 and CD10 expression was assessed, there 
was improved survival relative to Bcl-2 expression in the absence of CD10 
expression.   
 
In further support of the positive prognostic influence associated with CD10 
immunoexpression, Berglund et al. 80  and Ohshima et al. 67 found that CD10 
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expression in DLBCL predicted for improved survival, particularly in patients with low 
risk IPI scores.  
There is corroborative evidence supportive of the understanding that CD10- 
expressing lymphoid cells, both neoplastic and non-neoplastic, are inclined to 
become increasingly prone to apoptosis.  Often there is associated c-myc 
upregulation within these cells with resultant cellular induction into the cell cycle. 68,  
69,  70,  71,  72   This process creates the potential for improved response to apoptosis-
inducing therapy in CD10-expressing DLBCL and may well account for a significant 
survival advantage.  
                                   
 
Figure 4 – Muris’ algorithmic subdivision of DLBCL 66 
 
 
 
Sjo et al.73  examined 108 cases of DLBCL and found that both the Hans algorithm 
and the Muris algorithm displayed prognostic significance.  The cases in this study 
were scored positive for CD10, Bcl-6, and MUM1 if a minimum of 30% of the 
neoplastic cells were labelled, whereas the cut-off levels for Bcl-2 was 50%.  It was 
established that the Hans algorithmic stratification was associated with higher overall 
survival relative to the Muris algorithmic stratification.  
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In contrast to several studies mentioned, the findings of some investigators have not 
supported the notion of favourable outcome conferred by germinal center-like 
phenotypes in DLBCL. 
 Xu et al.74 suggested that CD10 and Bcl-2 expression were associated with poor  
 outcome with possible negative impact on treatment response.  In support thereof, 
 Uherova et al. 75 found that CD10 was predictive of inferior survival when    
combined with Bcl-2 expression.  Fabiani et al. 76 also found that CD10 expression 
was not associated with statistically significant differences in overall survival in 
patients with DLBCL.  The lack of statistical significance in this study may be 
attributed low levels of defining CD10 positivity in tumour cells.  A cut-off point of 
10% was used to define CD10-positive and CD10-negative cases of DLBCL. This 
percentage is much lower than that used in other studies in which favourable 
outcome has been established regarding CD10 expression in DLBCL (Table 6). 
Chini et al. 77 found that immunophenotypic subdivision of DLBCL into germinal 
center and non-germinal center types, using Hans’ and Muris’ methods of 
subdivision, failed to predict outcome.  In support thereof, Chadburn et al. 89  found 
no prognostic significance when cases of AIDS-related DLBCL were stratified into 
GC and ABC groups using Hans’ and Amen’s algorithms.   
 
Recently, Choi et al. 78 created a new algorithmic stratification of DLBCL based on 
immunohistochemistry (using tissue microarrays) which was found to have good 
concordance with gene expression profiles (using Lymphochip cDNA microarray ).  
This algorithm challenged that of Hans et al. 58  by employing the use of relatively 
new germinal center markers which showed high germinal center specificity. These 
markers included germinal center B-cell expressed transcript 1 (GCET1) and 
metastasis associated gene 3 (MTA3).  An additional marker, Forkhead box-P1 
(FOXP1), which is highly expressed in activated B-cell-like DLBCL was also 
employed.  However, a particularly high cut-off of ≥80% for FOXP1 was needed to 
achieve high specificity for the ABC subtype.  An equally high cut-off of 80% was 
used for GCET1.  Concordance between the new algorithm and gene expression 
profile in this study was 93%.  The overall survival using the newly proposed 
algorithm and gene expression profile-defined GCB and ABC DLBCL was similar to 
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the previous studies, in that improved survival was found in the GCB-DLBCL.  This 
algorithmic stratification was found to be more accurate than that proposed by Hans 
et al. 58 due to the use of new germinal center-specific markers and the fact that less 
emphasis was placed on the older germinal center marker Bcl-6.  The notable 
potential drawback is that particularly high cut-off levels for GCET1 and FOXP1 of 
80% were required for positive interpretation. 
 
INVESTIGATING GROUP     YEAR      PARAMETER               % CUT-OFF FOR INTERPRETATION AS  
        POSITIVE STAINING IN DLBCL 
 
  Hans et al                         2004     Bcl-2, Bcl-6,                                        30% 
                                                         CD10 & MUM 1           
                  
 
Chang et al                       2004    Bcl-6, CD10,  
                                                      MUM 1, CD138                  
                               20% 
 
Muris et al                       2006     CD10, Bcl-6,  
                                                      MUM1 
                                                      Bcl-2                                                
                               30% 
                      
     50% 
 
Sj  et al                           2007      CD10, Bcl-6         
                                                      MUM1   
                                                      Bcl-2                    
                      
                               30% 
                               50% 
 
 
Amen et al                      2007       Bcl-2, Bcl-6,  
                                                       CD10  MUM 1 
                               30% 
 
  Choi et al                        2009      CD10,  Bcl-6                                          30% 
                                                        MUM1                                                   80% 
                                                        GCET1 & FOXP1                                 80%   
 
Table 6- Investigating groups and immunophenotypic cut-off levels for positive    
staining in DLBCL  
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5.4.4 Prognostic significance of Bcl-2 expression  
Bcl-2 expression has been proven in the majority of studies to be an independent 
adverse prognostic factor in de novo DLBCL with shorter time to relapse occurring 
with high expression thereof.  Kramer et al. 79 suggested that high Bcl-2 expression in 
DLBCL is likely to confer resistance to chemotherapy.   
It is evident that a variety of defining cut-off levels has been used in various studies 
for assessment of significant Bcl-2 expression.  These cut-off levels range from 10-
60% in tumour cells of DLBCL . 80   
Hans et al. 58 found that Bcl-2 expression was an adverse predictor in the non-GCB 
subgroups of DLBCL.   In support thereof, Obermann et al.81 investigated the 
significance of Bcl-2 in DLBCL using combined fluorescence in situ hybridisation for 
BCL-2 gene assessment and immunohistochemistry for Bcl-2 protein expression.  
Non-GC type DLBCL with BCL-2 gene aberrations was found to be associated with 
significantly worse prognosis which was independent of the IPI score.   
 
Similarly, Hermine et al. 82 found that high Bcl-2 expression, occurring in greater than 
60% of tumour cells in DLBCL, was associated with reduced overall survival and 
reduced disease free survival.   
Gascoyne et al. 83  and Barrans et al. 84 also reported statistically significant 
correlations between increased Bcl-2 expression and decreased overall survival in 
patients with DLBCL.   The latter group furthermore demonstrated that patients with 
an intermediate IPI combined with expression of Bcl-2 experienced reduced survival 
which was similar to the poor survival rates of patients within the IPI high-risk 
categories.  Nyman et al. 85 further contributed that Bcl-2 expression which occurred 
in greater than 50% of tumour cells, continued to be of poor prognostic significance 
when patients with non-germinal center DLBCL were treated with 
immunochemotherapy (Rituximab and CHOP).  
 
In contrast, some studies demonstrated that Bcl-2 expression was unassociated with 
prognostic significance.  Kramer et al. 79 reported no significant correlation between 
Bcl-2 expression in DLBCL and overall survival.  Similarly, in AIDS-related DLBCL, 
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Little et al. 86 and Chadburn et al. 89 found that Bcl-2 expression did not prognosticate 
survival.   
 
5.4.5 Tumour proliferation index 
The tumour proliferation index in DLBCL is commonly assessed using Ki-67 
immunostaining.  Studies have shown that diffuse large B cell lymphomas with 
proliferation indices of greater than 60-80% are associated with poor prognosis and 
early death. 87, 88  
Conversely, in AIDS-related DLBCL, high proliferation indices (defined as positive 
staining in 90% of tumour cells) have been found to be associated with improved 
survival and better clinical outcome due to targeting of proliferating tumour cells by 
continuous infusional chemotherapy. 89  
 
5.4.6  MYC rearrangement and p53 expression in DLBCL 
Genetic features of DLBCL which adversely influence prognosis include MYC gene 
rearrangement which is associated with an aggressive clinical course and poor 
prognosis, appearing independent of the stage of DLBCL and age of the patient.  
Approximately 5% of DLBCL harbour a break of the MYC gene. Predictability of the 
presence of aberrations of the MYC gene by morphologic and immunohistochemical 
assessment at present is considered unreliable.  MYC gene status can be assessed 
using fluorescence in situ hybridisation (dual-colour break-apart probes).  90  Rao et 
al. 91  employed the use of comparative genomic hybridisation analysis and reported 
that c-MYC amplification was associated with advanced stage disease in patients 
with DLBCL.  
Using immunohistochemistry, Chang et al. 92 found that co-expression of c-MYC and 
p53 occurred in 58% of DLBCL with advanced clinical stage. Co-expression was 
absent in patients with low clinical stages.  In addition, co-expression also occurred 
more frequently in patients with high or high-intermediate risk IPI than in patients 
with low or low-intermediate risk. In further support thereof, Sanchez et al. 93  found 
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that the presence of p53 gene mutations in DLBCL was associated with poor 
prognosis.  
 
5.4.7 The prognostic significance of cyclin D2 expression in DLBCL  
Cyclin D2 is a cell cycle regulatory protein which is involved in facilitating G1 to S 
phase transition. Using tissue microarrays of 200 cases of de novo DLBCL, Hans et 
al. 156 established that patients with DLBCL expressing cyclin D2, defined as 
expression in ≥30% of tumour cells, were more likely to have B symptoms. By 
immunohistochemistry, cyclin D2 expression was found to occur in 19% of DLBCL.  
Within the context of IPI scores, patients with low IPI scores and cyclin D2 
expression by tumour cells were found to have significantly worse overall survival.  
Cyclin D2 expression was found to predict for worse overall survival and event-free 
survival in DLBCL and was limited to DLBCL with an activated B-cell-like or 
unclassified gene expression profile.  156 
 
 
5.4.8 The prognostic significance of highly active antiretroviral therapy (HAART) 
The literature abounds with conflicting findings regarding the prognostic influence of 
HAART on AIDS-related lymphomas.  
In a prospective observational study, Antinori et al. 94  established that concurrent 
administration of highly active anti-retroviral therapy (HAART) and chemotherapy 
could significantly modify the natural history of non-Hodgkin’s lymphoma in HIV 
infected patients.  HAART resulted in an increased response rate to chemotherapy 
and prolonged overall survival.  In addition, HAART could possibly increase the 
tolerability of higher chemotherapy dose intensities.  Similarly, Navarro et al. 95 
 demonstrated that patients treated with combination CHOP and HAART 
experienced higher rates of complete remission than those treated only with CHOP.  
Importantly, Besson et al. 96 found that the incidence of AIDS-related lymphomas 
had decreased significantly since the introduction of HAART.  Furthermore, patients 
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on HAART were found to have higher CD4 counts at the time of lymphoma diagnosis 
and improved overall survival.   
Contrasting findings by Mathews et al.97 and Ledergerber et al. 98 showed that the 
incidence of NHL in the era of antiviral therapy was largely unchanged.     
 
5.5  South African National Antiretroviral Treatment Guidelines 
In 2004, the South African National Antiretroviral Treatment Guidelines stipulated 
specific criteria for the initiation of antiviral therapy in patients infected with HIV. 
These criteria included CD4 <200 cells/mm3 irrespective of the WHO-defined 
disease stage or WHO Stage IV AIDS-defining illness (which included lymphoma) 
irrespective of the CD4 count.  These were accompanied by the essential criterion of 
patient willingness and readiness to take antiviral therapy adherently (Figure 5).  99                                                                                                                                                         
In 2010, the South African National Guidelines were amended to include initiation of 
antiretroviral treatment when CD4 counts less than 350cells/mm3 occurred in 
patients with TB/HIV co-infection and in pregnant women.  In addition, the criterion of 
the presence of drug-resistant tuberculosis (MDR/XDR), irrespective of the CD4 
count, was included (Figure 6). 100    
Figure 5   2004 Criteria for ART initiation in adults and adolescents 99 
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Figure 6   2010 Standardised national eligibility criteria for starting ART regimens in 
adults and adolescents 100 
 
 
 
5.6  The role of Epstein Barr Virus (EBV) in lymphomagenesis 
 
EBV is a herpes virus which usually infects children, affecting the majority of the 
world’s population.  Delayed exposure to EBV occurring in adolescence may result in 
symptomatic infectious mononucleosis.   Control of EBV infection of B lymphocytes 
involves natural killer cells and cytotoxic T lymphocytes.  However, removal of all B 
cells infected with EBV is not possible and a pool of memory B lymphocytes with 
latent EBV infection is established.  Lifelong carrier status follows primary EBV 
infection and the establishment of latent EBV infection in B lymphocytes is attributed 
to unique growth activating viral genes. 101  Initially EBV infects epithelial cells in the 
oropharynx and gains access to B-lymphocytes via the CD21 receptor. Within the B 
cell, the linear EBV genome circularises, persisting within the nucleus as an 
episome.  Viral gene expression may occur within lytic or latent cycles. 102  
Maintenance of latent EBV infection is sustained through several interesting 
mechanisms.  During latent cycle infection, EBV gene expression includes nuclear 
antigens (EBNAs) 1, 2, 3A, 3B, 3C and LP, as well as three latent membrane 
proteins (LMPs) which are associated with transforming activity. 103, 104  
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LMP1 is an important EBV transforming protein which induces changes 
 associated with B-cell activation.  These changes include increased expression of 
CD23, CD39, CD40 and CD44.  Due to the function of LMP1 as an activated 
member of the tumour necrosis factor receptor super-family, activation of ligand-
independent signalling pathways occurs.  LMP1 activates the nuclear factor (NF)-kB 
and JAK/STAT signalling pathways which promote B lymphocytic proliferation and 
survival.  LMP1 also upregulates expression of the anti-apoptotic protein Bcl-2 and 
stimulates production of cytokines interleukin 6 and interleukin 8.  105 
 
The nuclear phosphoprotein EBNA-1 promotes maintenance of the EBV episome 
within the B cell by binding to viral DNA while EBNA-2 functions as a viral 
transcription factor which induces expression of LMP1. EBNA-2 gene transactivates 
host genes such as Cyclin D which promotes cell cycle transition of B cells from G0 
to G1. 106 
 
The immortalisation of B lymphocytes by EBV is directly related to mechanisms of 
apoptosis suppression which includes expression of BHRF1 (an early lytic cycle 
antigen, member of the Bcl-2 family) in the lytic cycle.  In addition, EBV LMP1 
upregulates cellular Bcl-2 levels which inhibits apoptosis. 107  
Activation of two EBV immediate–early genes, BZLF1 and BRLF1 allows for the 
transition from latent to lytic EBV infection. 108 
 
Patients with primary and secondary immunodeficiencies are particularly prone to 
develop EBV-associated neoplasms.   EBV has a direct role in lymphomagenesis in 
these patients through mechanisms discussed.  In immunocompetent individuals 
development of EBV-associated neoplasms involves the role of EBV as a cofactor. 
 
 
5.7  The significance of NF-ĸB signalling pathway in DLBCL 
 
During normal cellular differentiation and immune responses, NF-ĸB (a transcription 
factor) is responsible for the integration of several intracellular signalling pathways. 
109 
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NF-ĸB transcriptional activity is mediated by dimers of the NF-ĸB family (p50/105, 
p52/100, p65/RelA, RelB or c-Rel).  In turn, regulation of NF-ĸB transcriptional 
activity is controlled by members of the IĸB family of inhibitors (particularly IĸBα) and 
the associated kinase (IKK) which binds to NF-ĸB allowing for its retention within the 
cell cytoplasm.  Once phosphorylated, IĸBα is prone to degradation via the ubiquitin-
proteasome pathway, releasing NF-ĸB dimers which then translocate to the nucleus 
and activate transcription of target genes. 110  
In B cell development and survival, NF-ĸB plays a critical role as the heterodimers of 
NF-ĸB participate in different stages of B cell differentiation and activation.  In B 
lymphocytes, NF-ĸB transcriptional function primarily involves heterodimers between 
one of the transactivating subunits (c-Rel or Rel A) and one of the non-
transactivating subunits (p50).  Generally in the absence of mitogenic stimuli, mature 
B cell lines show constitutively low levels of NF-kB (heterodimers p50 and c-Rel 
activity). 111 
The activation and phosphorylation of NF-ĸB occurs through pathways involving 
inflammatory stimuli and pathways triggered by tumour necrosis factor (TNF)-family 
members. 112  In order for mature B cells to proliferate and survive in response to 
mitogenic stimuli, acute increases in NF-ĸB activity are required.  MUM1/IRF4 is a 
mediator of B lymphocytic proliferative responses, induction of which is caused by 
binding of c-Rel (a transactivating subunit) to NF-ĸB.  In addition, an optimal increase 
in the number of B cells following B-cell receptor stimulation involves inhibition of 
apoptosis in which NF-ĸB activity has been implicated.  Bcl-2, BCL-XL and A1 are 
members of the anti-apoptotic Bcl-2 family which are targeted by NF-ĸB.  Induction 
of these anti-apoptotic agents occurs after B-cell receptor stimulation.  113, 114 
Imbalances in the anti-apoptotic and pro-proliferative functions of NF-ĸB have been 
found to contribute to malignant transformation with possible contribution to tumour 
progression particularly regarding Hodgkin’s disease and diffuse large B cell 
lymphoma. 115 
In DLBCL varying gene expression profiles have allowed for subdivision into 
germinal center B-like diffuse large B cell lymphoma (GC-DLBCL) and activated B 
cell-like DLBCL (ABC-DLBCL). 116  Davis et al 117 established that the activated 
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group of DLBCL displayed NF-ĸB activation due to high levels of IKK activity and 
IĸBα degradation which renders NF-ĸB readily available for translocation to the 
nucleus thereby activating transcription of target genes.  In ABC DLBCL, certain NF-
ĸB target genes are highly expressed.  These target genes include cyclin D2, 
IRF4/MUM1, Bcl-2, c-FLIP and IĸBα.  Low expression of these genes occurs in GC 
DLBCL.  In addition to Bcl-2, other members of this antiapoptotic family such as A1 
and BCL-XL are also NF-ĸB target genes.  
 ABC DLBCL showed high constitutive IKK activity and IĸB degradation which 
promotes increased NF-ĸB DNA binding activity.  In contrast, GC DLBCL lacked this 
form of NF-ĸB pathway activation. 
The constitutive NF-ĸB activation in ABC DLBCL may be due to derivation from a 
stage of B cell differentiation at which NF-ĸB is normally activated.  Alternatively, the 
activation of NF-ĸB may be an oncogenic event occurring in ABC DLBCL which is 
unrelated to the physiological role of NF-ĸB in B cell differentiation. 
In ABC DLBCL cell cycle progession requires activity of the NF-ĸB pathway via 
expression of Cyclin D2 (a NF-ĸB targeted gene).  During the G1 phase of the cell 
cycle, cyclin D activates cyclin dependant kinase 4, forming a complex (cyclin D-
CDK4) which plays a vital role in the phosphorylation of the retinoblastoma 
susceptibility protein (RB).  This protein in turn allows for activation of E2F 
transcriptional activity facilitating cell cycle progression beyond G1 and subsequent 
cellular replication.   
Most importantly, inhibition or loss of NF-ĸB activity has been found to be toxic to 
ABC DLBCL, due to G1 phase cycle arrest. Interestingly, loss of NF-ĸB function was 
found to be non-toxic to GCB DLBCL cell lines, thus creating the potential for 
targeted therapeutic intervention. 117 
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5.8.  Plasmablastic lymphoma 
 
5.8.1  General 
In 1978 Banks et al. published a case report of an extramedullary lymphoid 
neoplasm displaying morphologic features of diffuse large B cell lymphoma of 
“immunoblastic sarcoma” type.  This neoplasm was recognised as unique by the lack 
of immunohistochemical expression of B-cell surface markers and concomitant  
cytoplasmic expression of immunoglobulin (IgG) leading to recognition of a  
malignant lymphoma of plasmablastic identity.118  
 
In 1997 the term plasmablastic lymphoma was coined by Delecluse et al 119, 
following the description of an acquired immunodeficiency syndrome-associated  
B-lineage lymphoma with plasmacytic differentiation occurring in the oral cavity  
region of 16 patients.  It was proposed that this lymphoma represented a new  
subtype of diffuse large B-cell lymphoma. Thereafter, several cases of Human 
immunodeficiency virus (HIV)-associated plasmablastic lymphomas were reported 
by Brown et al 120,   Carbone et al 121, Chetty et al 122 and Lin et al 123 (among others) 
to involve topographic sites such as the oral cavity, jaw and extra-oral regions which 
included stomach, lung, perianal, nasal,  paranasal and cutaneous regions.     
Subsequently, plasmablastic lymphoma was considered a variant of diffuse large B- 
cell lymphoma. 124  Most recently, the 2008 WHO classification recognises 
plasmablastic lymphoma as a large cell non-Hodgkin’s mature B cell lymphoma, 
having been separated from the DLBCL category. 15 
 
 
5.8.2  Epidemiology 
The plasmablastic lymphoma incidence accounts for approximately 2.6% of all AIDS-
associated non-Hodgkin’s lymphoma. 125 
Plasmablastic lymphoma generally occurs in immunocompromised adult patients.   
Chabay et al. 126 and Radhakrishnan et al. 127 provided rare case reports of 
plasmablastic lymphoma occurring in paediatric patients with immunodeficiency.   
There are also rare case reports of plasmablastic lymphoma occurring in  
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immunocompetent and/or elderly patients. The topographic sites of involvement 
include the oral cavity and extra-oral sites. 128, 129, 130 
The median age at presentation is approximately 30-50 years.  However, a broad  
age range from 7 to 75 years exists. Delecluse et al. 119 report a 7:1 male  
predominance. 
 
5.8.3  Aetiology 
 
5.8.3 (a) Immunosuppression 
The vast majority of plasmablastic lymphomas occur in HIV-infected patients and  
represent aggressive malignant tumours with a poor prognosis.   
It is now established that other forms of immunodeficiency/immunosuppression  
 including iatrogenic immunosuppression associated with autoimmune disorders,  
ulcerative colitis and organ transplantation (most frequently renal transplantation) are  
also risk factors for development of plasmablastic lymphoma. 131   
 
5.8.3 (b)  Epstein-Barr virus (EBV) infection  
EBV plays an important role in the pathogenesis of plasmablastic lymphoma.   EBV-
positivity is demonstrable in the vast majority (60-100%) of plasmablastic lymphomas 
involving the oral cavity and extra-oral locations.  Several groups (Teruya-Feldstein 
et al.131, Dong et al.133 and Tavora el al.132 ) have confirmed the presence of EBER 
(Epstein Barr viral early RNA) by in situ hybridisation.   Detection of expression of 
EBV latency-associated proteins such as latent membrane protein-1 (LMP-1) by 
immunohistochemistry is very much lower.  Chetty et al. 122 found EBV LMP-1 
expression in 10% of extra-oral plasmablastic lymphomas.  Dong et al.133 confirmed 
EBV-EBER positivity in 12 of 14 cases while no LMP-1 immunoexpression was 
found in 7 of 14 cases tested. 133 
Interestingly, Rochford et al. 134  observed that EBER positive EBV infection, without  
detectable LMP-1, was associated with plasmacytic differentiation in EBV-infected  
B-cell lines.  
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5.8.3 (c)  Human herpesvirus- 8 (HHV-8)  
HHV-8 infection is implicated in lymphomagenesis.  Plasmablastic lymphoma may  
arise in the setting of multicentric Castleman’s disease in association with HHV-8  
infection.  Dupin et al. 135 demonstrated the presence of HHV-8 infection by HHV-8 
latent nuclear antigen 1 (LNA) immunohistochemistry in 8 patients within multicentric 
Castleman’s disease.  Three of their patients subsequently developed plasmablastic  
lymphoma.  In support thereof, Oksenhendler et al. 136 confirmed the development of 
plasmablastic lymphoma in 6 patients with HIV infection and multicentric 
Castleman’s disease.  HHV-8 LNA was demonstrated by immunohistochemistry in 3 
of these cases.  
 
The demonstration of HHV-8 infection in plasmablastic lymphomas occurring in  
patients with HIV infection, unassociated with Castleman’s disease, has been met 
with significant controversy.   Cioc et al. 137 initially demonstrated HHV-8 infection by 
immunohistochemistry and real time in situ PCR in 4 cases of plasmablastic 
lymphoma occurring within the oral region (oral cavity and oro/nasopharynx).   
Deloose et al. 138 confirmed the presence of HHV-8 infection by PCR and  
immunohistochemistry in 10 of 26 cases of diffuse large B cell lymphoma occurring  
in HIV infected patients.  These cases constituted a distinctive subgroup of DLBCL  
with immunoblastic/plasmablastic morphology, CD138/syndecan immunoexpression  
and low/absent expression of B-cell markers such as CD20, PAX5 and CD79a.   
All of these tumours were located predominantly within the gastrointestinal tract and  
there was no associated history of multicentric Castleman’s disease.  
Six of the patients had preceding Kaposi’s sarcoma. Due to the high sero-prevalence  
of HHV-8 infection and frequent association of Kaposi’s sarcoma with HIV infection,  
confirmation of HHV-8 infection of actual lymphoma cells required correlation of 
HHV-8 PCR findings with HHV8 immunohistochemistry. 138 
Toure et al. 139  subsequently confirmed the presence of HHV-8 RNA by PCR and  
immunohistochemistry for HHV-8 protein in one case of plasmablastic lymphoma  
occurring in the oral cavity of an HIV-infected patient.   
 
However, in several studies which followed, there was no demonstrable evidence of 
HHV8 infection in plasmablastic lymphoma, unassociated with multicentric 
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Castleman’s disease.  Colomo et al.51  showed that 11 cases of plasmablastic 
lymphoma (of oral mucosa type) lacked evidence of HHV-8 infection.  
 Although Dong et al. 133  found low levels of HHV-8 DNA by nested PCR in 6 of 10 
cases of plasmablastic lymphoma, immunohistochemistry for HHV-8 latent nuclear 
antigen was negative in all the tumour cells.  Two of the patients included in their 
study had concomitant Kaposi’s sarcoma and tumorous ascites.  They concluded 
that the HHV-8 DNA detected by PCR was most likely due to the presence of 
infected bystander circulating (non neoplastic) lymphocytes. 140  The discrepant 
findings, relative to those of Coic et al. 137 in which HHV-8 was demonstrated in most 
of the tumour cells, may be attributed to differences in methodology and the HHV-8  
antibody used.  Carbone et al. 141 were subsequently prompted to re-evaluate the 
possible presence of HHV-8 infection in plasmablastic lymphomas of the oral cavity. 
No evidence of HHV-8 infection was demonstrated in their study.  
 
Overall, although HHV-8 infection has been reported in some cases of plasmablastic  
lymphomas (unassociated with multicentric Castleman’s disease) occurring within 
the oral cavity, the majority of studies have not supported this finding.  
Thus, at present, the role of HHV8 in the pathogenesis of plasmablastic lymphoma 
remains uncertain. 
 
 
 
5.8.4  Clinical features of  plasmablastic lymphoma 
Plasmablastic lymphoma may occur in oral and extra-oral topographic regions.  
Most patients present with advanced stage disease as shown by Colomo et al.51   
Plasmablastic lymphomas present most commonly as primary disease with 
intermediate to high risk international prognostic indices.  Rarely, secondary 
plasmablastic transformation may occur in pre-existing plasma cell neoplasms as 
reported by Qing et al. 142 
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5.8.5  Morphologic features of plasmablastic lymphoma 
The histopathologic appearance of plasmablastic lymphoma is that of a high grade  
lymphoma.  The tumour displays a morphologic spectrum comprising a diffuse  
population of large blastic lymphoid cells with a monomorphic cohesive-like quality  
as well as cells with plasmacytic differentiation.  At low power magnification, a starry- 
sky appearance is discernable due to the presence of tingible body macrophages  
interspersed among tumour cells. 
At the blastic end of the spectrum the tumour cells display large round or oval  
eccentrically displaced nuclei with a single large central nucleolus or several  
peripherally located nucleoli.  The cells contain abundant amphophilic cytoplasm  
and paranuclear hofs which are  morphologically consistent with plasmablasts. 
Colomo et al. 51 aptly described the monomorphic features of cells of plasmablastic  
lymphoma of oral mucosa type as if they were frozen at the same stage of  
differentiation with minimal plasmacytic differentiation.   This morphologic variant  
tends to occur in association with HIV-infection.  
At the plasmacytic end of the spectrum, plasmablastic lymphoma with plasmacytic  
differentiation comprises plasmablasts and immunoblasts, the latter displaying larger  
nuclei and larger nucleoli than plasmablasts.  Distinct plasmacytic maturation is  
usually present.   Plasmablastic lymphomas with plasmacytic differentiation tend to  
occur in nodal and extranodal sites other than those of the oral mucosa (gingival,  
palatal and jaw regions).   
Mitotic figures are usually frequent and coagulative tumour necrosis may be present 
at both ends of the morphologic spectrum. 15, 52 
 
 
5.8.6 Immunohistochemical features of plasmablastic lymphoma 
Plasmablastic lymphomas generally lack expression of CD45RB (LCA) and  
pan B-cell marker CD20.  However, Colomo et al. 51 found weak expression of CD45 
in 61% of plasmablastic lymphomas, oral mucosa type, and in 56% of plasmablastic  
lymphomas with plasmacytic differentiation.  In this particular study, weak  
expression of CD20 in 8-13% of cases of plasmablastic lymphoma was also  
established.  Delecluse et al. 119 also confirmed weak surface membrane expression 
of CD20 and LCA, in less than 5% of tumour cells, in 3 of 8 cases of plasmablastic 
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lymphoma.   In a case report by Guan et al. 130 focal LCA expression was also found 
in plasmablastic lymphoma occurring in the oral cavity of an HIV negative patient.  
 
The tumour cells in plasmablastic lymphoma express plasma cell 
immunohistochemical markers which include VS38C, CD138, CD38 and  
IRF4/MUM1.  Several groups have demonstrated cytoplasmic expression of  
immunoglobulins (usually IgG) which occurs in approximately 70% of cases.   
EMA expression may occur and there is variable expression of CD79a which ranges 
from 50 to 80%.  143 
CD56 expression is common in myeloma and expression may occur in plasmablastic  
lymphoma with plasmacytic differentiation.  Plasmablastic lymphomas are high grade 
tumours with significantly high proliferation indices.  Ki67, most frequently used to 
assess the proliferation index, is usually greater than 90%.  The vast majority (up to 
75%) of plasmablastic lymphomas display evidence of EBV infection as 
demonstrated by EBER in situ hybridisation.  Associated EBV LMP1  
immunoexpression is very much lower.  15, 52 
 
 
5.8.7  Molecular findings in plasmablastic lymphoma 
Valera et al.155 identified MYC rearrangements in 49% of PBL and most of these 
were partnered by the immunoglobulin (IG) genes.  Furthermore, MYC 
rearrangements were found to be more common in EBV-positive (74%) than EBV-
negative (43%) plasmablastic lymphomas.  No rearrangements of BCL2, BCL6, 
MALT1 or PAX5 were detected in this serious of PBL cases. 
Similarly, Dawson et al. 144 reported the association of plasmablastic lymphoma with 
an IgH/MYC translocation in a patient with HIV infection and haemophilia.   
Gaidano et al. 145 performed sequencing analysis of the immunoglobulin heavy chain 
variable region (IgVH) gene in 10 cases of plasmablastic lymphoma occurring in 
patients with HIV infection.  Somatic hypermutation was found in four cases. This 
finding suggested that plasmablastic lymphoma is a molecularly heterogeneous 
disease derived from post-germinal centre cells or from native B-cells undergoing 
preterminal differentiation. One of the four cases also showed BCL-6 gene mutation 
implying its derivation from post-germinal centre cells.  
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Chang et al. 146 used array comparative genomic hybridisation to assess the 
genomic profile of plasmablastic lymphoma.  The most frequent segmental gains  
(> 40%) in PL included 1p36.11-1p36.33, 1p34.1-1p36.13, 1q21.1-1q23.1, 7q11.2-
7q11.23, 11q12-11q13.2 and 22q12.2-22q13.3.   
Segmental gains in 1p35.1-1p36.12, 1q21.1-1q23.1, 1p36.11-1p36.33, were found to 
occur only in PL.  Interestingly, segmental gains of 16p12-16p13.2 and 11q14-
11q14, occurred more frequently in HIV positive cases suggesting that these lesions 
may be related to HIV associated malignancies.  PLA2 gene has been shown to be 
activated by HIV envelope glycoproteins and may participate in the fusion of HIV and 
lymphocytes.  Segmental genetic losses were more heterogeneous with frequencies 
up to 23%.  Overall, the genomic aberration pattern appeared to be more similar to 
that of DLBCL (AIDS-related and non AIDS-related) than myeloma.  Gain of 16p13.3 
was found to occur in some cases of plasmablastic lymphoma and DLBCL. This 
alteration was not found in any of the cases of myeloma. 
  
Vega et al. 147 found that AIDS-related plasmablastic lymphoma had 
immunophenotypic features and tumour suppressor gene expression profiles which 
were similar to plasmablastic plasma cell myeloma.  Both tumours displayed high Ki-
67 proliferation indices with overexpression of p53 and loss of expression of p16 as 
well as p27.  However, the tumours differed in that EBV-encoded RNA was positive 
in all plasmablastic lymphomas and negative in plasma cell myelomas.  
 
In contrast, isolated case reports have challenged the latter finding of Vega et al.147 
in that EBV infection (EBER) has been documented in a case of submandibular 
plasmacytoma and in a case of multiple myeloma occurring in a patient with AIDS.  
157,158 
 
 
5.8.8  Outcome of plasmablastic lymphoma 
Plasmablastic lymphomas are associated with poor outcome despite aggressive 
therapy which combines systemic chemotherapy and/or radiotherapy and HAART in 
the setting of HIV infection.  Most investigative series have demonstrated median 
survival of less than 12 months.  15, 52 
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6. AIMS AND OBJECTIVES 
The aims and objectives were to investigate large cell lymphomas which included 
diffuse large B cell lymphoma and plasmablastic lymphoma and to correlate the 
Human Immunodeficiency Virus status and prognosis with differentiation profiles 
assessed by immunophenotyping.   
This study was submitted for review to the Research Ethics Committee of the Health 
Sciences Faculty at the University of Cape Town and formal ethical approval thereof 
was obtained (REC reference 209/2006). 
 
7. METHOD 
7.1 Case selection 
The researcher retrieved cases of large cell lymphoma comprising diffuse large B 
cell lymphoma and plasmablastic lymphomas which were diagnosed at the 
histopathology department, division of Anatomical Pathology, National Health 
Laboratory Service, Groote Schuur Hospital, Cape Town.  The cases were selected 
from a snomed-based search of the DISA computer system and from 
the intradepartmental lymphoma database.  Random selection of cases from both 
HIV positive and negative patients was made.  Cases of DLBCL with Burkitt-like 
features were omitted from the study.  Tissue samples which were limited by paucity 
of diagnostic tissue were also excluded from the study. 
 In total 61 cases were included in this study.  Of these, 27 cases were diagnosed 
in HIV positive patients. These comprised 9 de novo plasmablastic lymphomas 
and 18 diffuse large B cell lymphomas.  In HIV negative patients, 28 cases of diffuse 
large B cell lymphomas were selected. Two of these patients were recipients of solid 
organ allograft transplantation (renal and cardiac).  In 6 additional patients with 
DLBCL, the HIV status was unknown.  Overall, the total number of cases of DLBCL 
was 52. 
All cases were diagnosed between January 2004 and December 2007, allowing for 
a mean follow up of 27 months from the time of diagnosis. 
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7.2  Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue blocks for each of the selected cases were 
retrieved from the departmental archives.  A panel of immunohistochemical 
stains was performed, at times augmenting those done at initial 
histopathologic work-up and diagnosis.  
A total of eleven, 3-4 micron, sections were cut from each representative block, 
floated onto silanised slides, heat fixed at 75oC for 30 minutes and then stored at 
room temperature until immunohistochemistry (IHC) was performed. Silanised slides 
are those which are coated with organosilane and baked for approximately 30 
minutes at temperatures of 55-60 degrees Celsius to ensure optimal adhesion of 
tissue sections.   All immunohistochemistry was performed on a Dako Autostainer 
(Universal Staining System) using the Envision Detection System.  Sections were 
dewaxed in xylene, taken down to water through graded alcohols and subjected to 
antigen retrieval.  Heat induced epitope retrieval, HIER, was performed in a Tedelex 
Pressure cooker using either 10mM Citric Acid at pH6 or 1mM EDTA at pH8.  
Buffers were brought to boiling point, slides were immersed in the boiling buffer and 
full pressure was maintained for 2 minutes. Thereafter slides were immediately 
immersed in running tap water. The staining protocol included blocking for 
endogenous peroxidase with an aqueous 2% H202 solution for five minutes; blocking 
for non-specific binding with 5% normal goat serum (Dako X0907) in phosphate 
buffered saline (PBS, IHC washing buffer) for five minutes; incubation with the 
primary antibody (as specified in the table 8) for 45 minutes and incubation with the 
secondary antibody (Envision K4001) for 30 minutes. The chromogenic substrate 
(Dako K3466) was applied for 5 minutes.  All rinse steps were done with 
PBS/Tween.  Positive and negative controls were included in each run.  PBS/Tween 
or non-immune serum replaced primary antibodies for the negative controls. 
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Antibody              Clone  Dilution (PBS)    Antigen Retrieval  Control 
CD10  56C6  1:30  10mM Citrate                Tonsil 
CD38  SPC32   1:60  1mM EDTA             Tonsil 
CD138              MI 15  1:50  1mM EDTA             Appendix 
Bcl-2  124  1:20  10mM Citrate             Appendix 
Bcl-6  PG-B6p  1 :20  1mM EDTA                   Appendix 
Mib-1  Ki-67  1 :50  10mM Citrate             Appendix 
EBV  LMP-1  1 :200     1mM EDTA                   Positive  lymph node 
MUM-1              MUM 1p 1 :50  1mM EDTA             Appendix 
Plasma Cell VS38C   1 :30  1mM EDTA             Tonsil 
 
Table 7 Antibodies used in the study 
 
8.  RESULTS 
 
8.1 Morphologic features 
The morphologic features of the selected tumours were assessed by light 
microscopy using haematoxylin and eosin (H&E) stained sections.   
Within nodal and extranodal locations, the diffuse large B cell lymphomas displayed 
diffusely destructive and widely permeative growth patterns. Necrosis and apoptotic 
debris were prominent features in some cases, particularly in DLBCL occurring with 
the HIV positive patients in keeping with the high grade nature of these tumours.  
The individual tumour cells displayed large nuclei which were generally larger than 
those of histiocytes. The nuclei were predominantly round and occasionally indented.  
The nucleoli varied from single, centrally located prominent nucleoli to multiple 
smaller peripherally located nucleoli. Moderate amounts of eosinophilic to pale 
amphophilic cytoplasm were present. The vast majority of the diffuse large B cell 
lymphomas displayed mixed centroblastic and immunoblastic morphologic features.   
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Figure 7 H&E stained section (X200 magnification) of DLBCL displaying mixed centroblastic 
(longer arrow) and immunoblastic (shorter arrow) features. 
Prominent immunoblastic morphology was evident in DLBCL occurring within the 
small intestine of an HIV negative patient with previous solid organ (renal) allograft 
transplantation (Figure 8).  EBV LMP1 immunohistochemistry was positive in these 
tumour cells. 
 
Figure 8 H&E stained section (X200 magnification) of DLBCL with immunoblastic   
morphology. 
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The plasmablastic lymphomas displayed features of high grade tumours with sheet-
like growth patterns and interspersed tingible body macrophages which imparted a 
starry-sky appearance to the tumour (Figure 9).  The individual tumour cells 
displayed blast-like cytomorphologic characteristics (Figure 10) .  There was 
abundant amphophilic to basophilic cytoplasm and eccentrically displaced large 
round vesicular nuclei within which were prominent nucleoli.  The number of nucleoli 
varied from a single prominent nucleolus to several distinctly prominent nucleoli.  
Significant mitotic activity and apoptotic debris were often present.  
Isolated cases of extra-oral plasmablastic lymphomas showed variable, intermittently 
subtle, degrees of plasmacytic differentiation (Figure 11) combined with prominent 
immunoblastic and plasmablastic morphologic features.  
 
 
Figure 9 H&E stained section (X100 magnification) depicting plasmablastic lymphoma with a 
starry-sky appearance imparted by interspersed tingible body macrophages (arrows) 
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Figure 10 H&E stained section (X400 magnification) of plasmablastic lymphoma with distinct 
blastic morphology 
 
 
Figure 11 H&E stained section (X200 magnification) of plasmablastic lymphoma depicting 
greater degree of plasmacytic differentiation. 
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8.2 Immunohistochemistry 
Immunohistochemistry was interpreted with the aid of a scoring system in which 
scores of 0-4 were allocated in relation to the percentage of positively staining 
tumour cells. Scores of 0-5 were used when assessing the proliferation index (Ki67). 
 
Score                         % of tumour cells displaying positive staining                 
        0                -                negative           
        1                -                1   -  25           
        2                -                26 -  50      
        3                -                51 -  75    
        4                -                76 - 100           
 
      
Table 8 IHC scoring system 
 
 The cut-off level for interpreting CD10, Bcl-6 and Bcl-2 as positive was >25% tumour 
cell staining which is equivalent to a score of at least 2. 
Immunohistochemistry was interpreted as positive when the following staining 
patterns occurred with respective antibodies:  
 
       MUM1 - nuclear staining 
       CD20, CD3, CD38 – cell membrane staining 
       CD10   - cell membrane and cytoplasmic staining 
       Bcl-6    - nuclear staining 
       Bcl-2    - cytoplasmic staining 
       VS38C - cell membrane and cytoplasmic staining 
       CD138 – cell membrane and cytoplasmic staining 
       EBV LMP1 – cell membrane and cytoplasmic staining 
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Ki67 score  -       % of tumour cells displaying positive nuclear staining 
       0               -                 negative 
       1               -                 1   - 25 
       2               -                26  - 50 
       3               -                51  - 75 
       4               -                76  - 95 
       5               -                   >95 
       
Table 9 Scoring of Ki67 
 
All the cases of DLBCL displayed diffuse expression of CD20 (Figure A).  There 
were high proliferation indices which occasionally exceeded 95% in HIV positive and 
negative groups (Figure D).  CD10 expression, involving at least 25% of tumour cells 
(score ≥2), was found in 38% (23/52) of DLBCL cases.  Similarly, Bcl-6 expression 
was established in 60% (31/52) while MUM1 expression occurred in 88% (46/52) of 
cases.  CD38 expression (Figure C) was found in 98% (51/52) of DLBCL in this 
study and EBV LMP1 expression occurred in 5/52 cases. 
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Figure  A    DLBCL with membrane immunoreactivity for CD20  
Figure  B    DLBCL with EBV LMP1 immunoreactivity.  This tumour  
                   displayed immunoblastic morphologic features. 
 
Figure  C    DLBCL with diffuse CD38 immunoreactivity 
Figure  D    High proliferation index in DLBCL demonstrated by Ki-67 immunohistochemistry 
 
All cases of PBL in our study lacked CD20 expression (Figure F) and 8/9 cases 
displayed MUM1 immuno-expression (Figure E) which involved 76-100% of tumour 
cells.  In the single case which lacked MUM1 expression, VS38C, CD138 and CD38 
immunoexpression was found to occur in 76-100% of tumour cells.  Interestingly, of 
all our PBL cases, the MUM1-negative case showed the highest level of EBV-LMP1 
expression which involved 51-75% of tumour cells.  Overall, EBV LMP1 
immunoexpression was detected in 3/9 PBL cases.  VS38C, CD38 and CD138 
expression was found in all cases of PBL.  The proliferation index in all cases of PBL 
was high and ranged from 76 to >95%. 
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     Figure  E – PBL displaying diffuse nuclear immunoreactivity for MUM1  
     Figure  F – PBL displaying an absence of CD20 immunoreactivity  
 
8.3 Statistical interpretation 
The data generated from this scoring system was captured in an Excel-spread sheet 
(Tables 10 and 11).  Information regarding several prognostic factors such as age, 
CD4 count, IPI score, highly active anti-retroviral therapy (HAART), chemotherapy 
(CHOP) and radiation treatment was obtained by close collaboration with a senior 
radiation oncologist at Groote Schuur Hospital.  All the information obtained, was 
incorporated into the data spread sheet.  
Statistical analysis of the gathered data was conducted by the researcher and a 
statistician using computer programme SPSS version13.  Kaplan Meier curves for 
survival, log rank test and the Cox regression model were used.   
The Cox model was used for analysis of survival data by simultaneously exploring 
the effects of various prognostic factors, which included immunohistochemical 
E 
F 
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variables, on survival.  Overall, the Cox regression model essentially allowed the 
researcher to assess the effect of several prognostic variables at a time on survival.  
It allowed for the estimation of the hazard/risk of death for individual patients in light 
of the status of their prognostic variables. 
In this study the survival time refers to the time to death.  Survival time was censored 
indicating that at the end of the study period, there were surviving patients.  From the 
obtained set of survival times, it is possible to estimate the proportion of the 
population of patients with DLBCL and PBL who are likely to survive a given length 
of time under similar circumstances.   
Kaplan-Meier estimation of the survivor function allowed for a table, specifically a life 
table, and a graph or survival curve to be produced.  In this study, the comparison of 
the survival curves between two groups was assessed by means of the log-rank test.  
The log-rank test essentially tested the null hypothesis that each of the groups in this 
study had the same force of mortality.  This contrasted the Cox regression model 
which allowed the researcher to estimate the risk of death for a patient, given the 
respective prognostic variables.  P values less than 0 .05 were indicative of statistical 
significance. 
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Table 10 Data sheet (A)  
----------------------------------------------------------------------------------------------------------- 
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 1 4 3 4 0 3 0 4 2 0 4 4 DLBL 3 39 F -   
 2 4 2 3 0 2 0 4 0 0 2 4 DLBL 1 67 M /   
 3 4 2 2 0 3 2 1 4 0 4 1 DLBL - 69 F /    
 4 4 3 2 0 2 0 3 3 0 4 4 DLBL 0 64 M -   
 5 4 0 1 0 2 4 3 4 0 1 0 DLBL 4 67 F -   
 6 4 1 2 0 1 2 3 4 0 3 1 DLBL - 49 M -   
 7 4 1 4 0 1 4 4 4 0 5 0 DLBL 3 53 F  -  
 8 4 4 4 0 3 0 4 4 0 4 4 DLBL 2 61 F -   
 9 4 0 3 0 3 0 3 3 0 4 4 DLBL 3 51 M  /  
 10 4 0 4 0 2 0 4 4 0 4 4 DLBL - 33 F  -   
 11 4 4 4 0 3 0 4 3 0 3 4 DLBL 3 54 M  /  
 12 4 4 3 0 3 0 4 4 0 5 4 DLBL 1 34 F  /  
 13 4 1 3 1 1 0 2 4 0 4 4 DLBL - 71 M -   
 14 4 4 2 0 3 0 4 0 1 4 0 DLBL 2 43 M -   
 15 4 2 3 1 1 4 4 4 0 3 4 DLBL 4 67 F -   
 16 4 2 1 0 2 0 2 0 0 4 4 DLBL 4 50 F -   
 17 4 3 3 0 2 0 3 1 0 4 4 DLBL - 44 F -   
 18 1 1 4 0 3 0 0 0 0 4 1 DLBL 2 36 M -   
 19 4 1 1 0 3 0 4 1 0 3 1 DLBL 3 45 M -   
 20 4 2 1 0 2 0 4 1 0 4 4 DLBL 2 45 F -   
 21 4 2 2 0 3 0 1 2 0 4 3 DLBL 4 60 M -   
 22 3 3 3 1 2 3 4 1 0 4 4 DLBL 3 59 F -   
 23 4 2 2 0 1 0 3 3 0 4 3 DLBL 5 86 F -   
 24 4 4 4 0 3 0 1 0 0 3 2 DLBL 3 20 F -   
 25 4 0 2 0 2 0 2 2 0 2 1 DLBL - 70 F -   
 26 4 1 1 0 2 0 3 0 0 2 1 DLBL 3 57 M -   
 27 4 1 1 1 2 0 2 2 0 4 1 DLBL 0 60 M -   
 28 2 3 3 0 2 1 4 0 0 4 2 DLBL 4 23 M -   
 29 4 1 2 0 3 3 2 0 0 3 1 DLBL 4 76 F -   
 30 1 1 2 0 3 0 1 0 0 1 1 DLBL - 68 F -   
 31 4 3 1 0 3 3 0 3 0 3 2 DLBL 3 58 F -   
 32 4 3 4 0 1 3 4 1 0 3 4 DLBL 0 76 M  /  
 33 4 1 4 0 2 1 0 2 0 3 1 DLBL - 35 M -   
           34      4         2       2        0        3        4        4        4         0       3            2       DLBL      5      80            F      - 
 
          A -    Age 
          G -   Gender 
          R -   Retroviral status (- negative; + positive, / unknown)  
    DLBL-    Diffuse large B cell lymphoma 
     CD3 -    Background reactive T lymphocytes in the tumour 
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Table 11 Data sheet (B)   
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                                                                                                                                                                                                CD4 
 
 
           35       4        1       2         0        2        0        0         1       0           5          1      DLBL      2        33        F          +      77  
           36       4        1       3         1        2        1        0         4       0           4          1      DLBL      1        36        F          +      50    
           37       3        3       4         0        3        3        1         0       3           3          3      DLBL      1        67        M         +      67    
           38       4        1       4         0        2        0        4         0       1           5          4      DLBL      -         38        M         +    131 
           39       4        2       4         3        2        0        0         0       0           3          3      DLBL      4        30        F          +    152         
           40       0        3       4         4        1        0        0         0       0           4          4      PBL        4        32        F          +      54     
           41       4        3       2         2        3        3        0         4       0           4          4      DLBL      3        34        F          +      92    
           42       4        1       4         2        1        3        0         2       0           3          1      DLBL      5        41        M         +        -        
           43       0        4       4         4        1        3        2         0       0           4          4      PBL        1        36        F          +      69   
           44       4        0       2         0        2        0        4         3       0           4          2      DLBL      2        67        M         +    180        
           45       0        4       4         4        3        4        0         2       0           5          4      PBL        2        35        M         +      23  
           46       0        4       4         1        2        0        1         1       0           4          4      PBL        0        34        M         +      42 
           47       3        0       4         0        2        0        0         1       2           3          4      DLBL      0        40        F          +      23 
           48       4        3       4         0        3        3        4         3       0           4          4      DLBL      3        58        F          +    438 
           49       4        2       4         0        3        2        4         4       0           4          3      DLBL      3       53         M         +    145 
           50       4        1       4         0        2        2        0         3       0           2          0      DLBL      0       34         M         +    200 
           51       4        4       4         0        2        4        0         0       0           3          0      DLBL      4        29       M          +    434 
           52       0        4       4         4        1        4        2         0       0           4          4      PBL        1       42         F          +      27 
           53       4        2       0         0        2        0        0         0       0           1          1      DLBL      3       32         M         +      41 
           54       0        4       1         4        3        1        0         0       1           4          4      PBL        2       32         F          +    114 
           55       0        4       4         4        1        0        0         0       3           0          0      PBL        3       35         F          +      28 
           56       4        1       3         3        0        0        0         3       0           4          4      DLBL      2       46         M         +    138 
           57       4        1       3         1        3        0        3         0       2           4          3      DLBL      1       49         F          +    114 
           58       0        4       4         0        3        0        0         0       1           4          4      PBL        0        35        M         +    166 
           59       0        4       4         3        2        4        0         0       0           5          4      PBL        2       44         M         +      29 
           60       4        1       4         0        1        4        0         4       0           5          1      DLBL      2       48        F           +    130 
           61       2        2       3         0        1        2        1         4       0           5          0      DLBL      2       42        M          +    108 
  
          A -    Age 
          G -   Gender 
          R -   Retroviral status (- negative; + positive, / unknown) 
    DLBL-    Diffuse large B cell lymphoma 
      PBL-    Plasmablastic lymphoma  
     CD3 -    Background reactive T lymphocytes in the tumour 
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8.4 Statistical results 
The mean age of patients with DLBCL in the HIV negative group was 54 years.  
However, in the HIV positive group, the overall mean age of patients was 43 years. 
Further assessment revealed that the mean age of HIV positive patients with DLBCL 
and PBL was 48 and 36 years, respectively. 
In the HIV positive group there were 11 males and 10 females with DLBCL.  Five 
cases were diagnosed on lymph node biopsies and 16 cases were diagnosed on 
biopsies of extranodal topographic sites.  The extranodal sites included liver (3 
cases), nasopharynx (7), soft tissue, kidney, pancreas, spleen (2) and adrenal gland.    
In the HIV negative group, DLBCL was diagnosed in 18 females and 16 male 
patients.  15 cases were diagnosed on biopsies of lymph nodes and 18 cases were 
diagnosed on biopsies of extranodal sites.  In one additional case, the distinction 
between nodal and extranodal involvement was uncertain as the incisional biopsy 
originated from the retroperitoneum.  The extranodal sites included skin, kidney, 
testis (2 cases), nasopharynx (3), tonsil (2), adenoids (2), central nervous system 
(2), small intestine, spleen, bone (vertebra and clavicle) and breast.  
Plasmablastic lymphoma was diagnosed in 4 male and 5 female patients, all of 
whom had HIV infection.  2 cases were diagnosed on biopsies originating from the 
oral cavity (gingiva and floor of mouth) and 7 cases were diagnosed on biopsies from 
extra-oral sites.  The extra-oral sites included bone (1 case; clavicle), rectum, anus, 
skin, extradural T8 spinal region, scalp and suprasternal region.    
In this study, the researcher established that the overall mean CD4 count in patients 
with HIV infection was 121cells/mm3.  This was further stratified revealing a mean 
CD4 count of 151cells/mm3 in HIV positive patients with DLBCL and mean CD4 
count of 61cells/mm3 in patients with PBL.  
In the absence of HIV infection, the overall survival of patients with DLBCL was 
significantly better than DLBCL occurring in patients with HIV infection.  The log-rank 
test confirmed the presence of a statistically significant p value <0.0001. 
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Table 12: Predictive value of individual and combined immunohistochemical markers 
in DLBCL 
 
 
Characteristics         Number                   OS (%)            Median                      P-value 
                                                                                        survival time  
                                                                                           (months)            
 
Hans’ algorithm 
    GCB                           25                              43                     27                       0.188 
   Non GCB                    27                              22                     11 
Muris’ algorithm 
    Group 1                    27                              39                      21                      0.399 
    Group 2                    25                              24                      11 
HIV 
   Negative                   28                                40                     16                      <0.001 
   Positive                     18                               11                      7 
CD10 
   Negative                   30                                33                    11                      0.442 
   Positive                     22                                26                    10 
Bcl- 6 
   Negative                  19                                13                     16                     0.487 
   Positive                    33                                39                     18 
MUM 1 
   Negative                  23                                 37                     13                     0.124 
   Positive                    29                                 28                     11 
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Characteristics            Number           5-yr OS (%)            Median                  P-value 
                                                                                             survival time  
                                                                                                (months)            
Bcl- 2 
    Negative                   20                                18                       9                        0.371 
    Positive                     32                                38                     16 
CD 38 
    Negative                    1                                 14                      11                       0.769 
    Positive                    51                                 33                      13 
Bcl-2 in GCB 
   Negative                   10                                 20                       7                        0.007 
   Positive                    15                                  64                      27  
Bcl-2 in non-GCB 
   Negative                    7                                 14                       21                       0.268 
   Positive                    20                                25                        11 
IPI 
    Low risk: 0 – 2       31                                38                         13                     0.794 
    High risk: 3 – 5      21                                24                         16 
CD4 
   <200                         24                                                              0                       0.750 
   ≥200                          3                                                              14                          
Ki-67 
    <4                            21                                 39                        21                      0.079          
   ≥4                             31                                 26                         9            
Diagnosis 
   PBL                            9                                  0                         6                          0.002 
   DLBCL                      52                               33                        18  
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
63 
 
 
 
 
Graph 1 Kaplan Meier curves for overall survival: DLBCL occurring in HIV negative 
and HIV positive patients   
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Despite antiretroviral therapy, the overall survival of HIV-positive patients with 
DLBCL was significantly poorer than that of HIV-negative patients. Log-rank test 
confirmed statistically significant p value of <0.001. 
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Graph 2  Kaplan Meier curves for overall survival in patients with plasmablastic 
lymphoma and DLBCL 
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The study revealed that the overall survival of patients with plasmablastic lymphoma 
was poorer than that of DLBCL. Log-rank test confirmed a statistically significant p 
value of 0.002. 
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Graph 3  Kaplan Meier curves for overall survival in GCB and non-GCB DLBCL 
using the Hans’ algorithm 
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When Hans’ algorithm was used to stratify cases of DLBCL, the overall survival of 
patients with GC-subtype DLBCL was better than that of non-GC subtypes.  
However, the difference in survival was not statistically significant as the log-rank p 
value was 0.188. 
 
Similarly, when Muris’ algorithm was used to stratify cases of DLBCL, the overall 
survival of patients with group 1-type DLBCL was better than that of group 2-type 
DLBCL.  However, once again there was no statistical significance as the log rank p 
value was 0.399. 
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Graph 4 Kaplan Meier curves for overall survival in Group 1 and Group 2 DLBCL 
using  Muris’ algorithm   
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Graph 5  Kaplan Meier curves for overall survival using CD10 expression in DLBCL  
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Independent assessment of CD10 expression in DLBCL revealed no statistical 
significance as the log-rank p value was 0.442.   
Graph 6  Kaplan Meier curves for overall survival in DLBCL using Bcl-6 
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Bcl-6 expression in DLBCL was found to be associated with improved overall 
survival.  However, this was also not found to be statistically significant as the p 
value was 0.487.  
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Graph 7 Kaplan Meier curves for overall survival in DLBCL using MUM 1 expression 
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MUM1 expression in DLBCL was associated with lower overall survival.  However, 
there was no statistical significance (p value 0.124). 
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Graph 8 Kaplan Meier curves for overall survival in DLBCL when Bcl-2 expression 
occurred in the Hans-defined GCB group 
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No statistical significance was found when Bcl-2 expression was assessed 
independently of the IPI score, CD10, Bcl-6 and MUM1 expression (p value 0.371) 
However, an interesting finding was established when Bcl-2 expression occurred in 
germinal center-type DLBCL, using the Hans algorithmic stratification, in that 
improved survival was conferred by the germinal center phenotype.  The 
accompanying statistically significant p value was 0.007.   
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The overall survival of patients with low risk IPI scores (0-2) was better than those 
with high risk IPI scores.  However, this difference was not statistically significant as 
the p value was 0.794. 
 
Graph 9 Kaplan Meier curves for overall survival with low risk and high risk IPI 
scores 
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When the proliferation index in DLBCL was such that ≥76% of tumour cells (score 
≥4) displayed nuclear staining using Ki67 immunohistochemistry, the overall survival 
was poorer than that which occurred when the proliferative index was <4.  The log-
rank p value was 0.079.   
Graph 10 Kaplan Meier curves for overall survival in DLBCL using Ki67 <4 and ≥ 4   
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Statistic observation revealed that CD138 expression in >25% of tumour cells (score 
≥2), occurred only in the HIV positive group and was associated with shorter survival 
time. However no statistic significance was evident (p 0.402).  
Poorer survival outcome was demonstrated in the HIV group when the CD4 count 
was less than 200cells/mm3 in contrast to that which occurred when the CD4 count 
was greater than 200cells/mm3. However, the survival difference was not statistically 
significant as the p value was 0.750.   
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
72 
 
 
 
EBV LMP1 expression was found in 3/9 cases of PBL and 5/52 cases of DLBCL. In 
the latter group, 4/5 EBV LMP1-positive DLBCL occurred in patients with HIV 
infection. 
           
                          Table 13 Number of PBL and DLBCL expressing EBV LMP1 
 
  EBV  Count 
Diagnosis 
DLBCL LMP1 
Negative 47 
Positive 5 
Plasmablastic lymphomas LMP1 
Negative 6 
Positive 3 
      
 
 
CD38 expression occurred in all cases of DLBCL in the HIV negative group and 16 
cases of DLBCL in the HIV positive group; there was no associated statistical 
significance. 
 
9.  TREATMENT 
All patients with DLBCL were treated with CHOP therapy (cyclophosphamide, 
vincristine, doxorubicin/adriamycin and prednisone).  Intrathecal chemotherapy was 
used prophylactically in patients with nasopharyngeal or extradural involvement and 
in patients with central nervous system (CNS) disease. Prophylactic treatment is 
generally used in patients with non-Hodgkin’s lymphoma due to the likelihood of 
more aggressive disease and high rates of CNS relapse.  The use of intrathecal 
chemotherapy is advocated in all HIV positive patients with NHL.  At our institute, 
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five cycles of intrathecal chemotherapy is given as prophylaxis in combination with 
intravenous chemotherapy. If patients are found to have malignant cells in 
cerebrospinal fluid, therapy is administered until the CSF is clear of tumour cells. 
Two additional doses are given thereafter.  
The patients in our study also received varying therapeutic combinations which 
included dose-reduced chemotherapy, palliative radiotherapy, involved field 
radiotherapy and intrathecal chemotherapy.   
Patients with PBL were treated with CHOP therapy and involved field/ radiotherapy.  
Frequent loss of follow up of patients was a limiting factor.  
All patients in the HIV positive group received highly active antiretroviral therapy 
(HAART).  Some patients received HAART prior to the diagnosis of lymphoma while 
others commenced HAART at the time of lymphoma diagnosis.  
 
9.1 Co-morbidities occurring during the course of the study 
Opportunistic infections frequently complicate the outcome and survival of patients 
with lymphomas, particularly in the setting of background HIV infection.  During the 
period of our study (2004 – 2007), 11 patients in the HIV positive group were 
diagnosed with tuberculosis and 1 patient was diagnosed with Kaposi’s sarcoma.  
However, deaths which occurred in the HIV positive group were clinically and 
radiologically attributed to lymphoma rather than overwhelming opportunistic 
infection.  
 
10.  DISCUSSION 
Diffuse large B cell lymphoma is an aggressive malignancy which represents 20-
30% of NHL in Western countries. 50   The occurrence of DLBCL in African countries 
is amplified by confounding co-morbidity of immunosuppression due to HIV infection, 
a well established risk factor for the development of DLBCL.   
Cote et al.50 demonstrated a phenomenal 165-fold increase in the relative risk of 
developing lymphoma within three years of an AIDS diagnosis compared with 
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patients unaffected by AIDS.   AIDS-associated lymphomas which encompass 
DLBCL, PBL, BL and PEL, represent one of the commonest AIDS defining illnesses.  
These occur with increased frequency in patients infected with HIV and are 
exacerbated by low CD4 counts.  The literature abounds with reported studies of 
various prognostic factors proven to successfully predict outcome in DLBCL.  While 
synchronously providing a South African perspective, this study builds on and 
contributes to an elaboration of prognostic factors in DLBCL and PBL.  These 
prognostic factors are inclusive of the long-standing, internationally accepted IPI 
which combines several clinical parameters to stratify patients into (low, intermediate 
and high risk) prognostic groups.  In congruence with the literature, the present study 
confirmed that low risk IPI indices (scores 0-2) were associated with improved 
overall survival relative to high risk IPI indices (scores 3-5). 55, 56, 58  However, this 
finding was not statistically significant as the p value was 0.794.  
 Assessment of the mean age at presentation revealed that HIV positive patients 
were significantly younger (greater than a decade) compared to the age at 
presentation of DLBCL in HIV negative patients (HIV positive – mean age 43 years; 
HIV negative – mean age 54 years).   
In the HIV positive group, the mean CD4 count at diagnosis was 121cells/mm3.  
Patients with PBL had a significantly lower mean CD4 count of 61cells/mm3 in 
contrast to the mean CD4 count of 151cells/mm3 which occurred in patients with 
DLBCL.  Poorer survival outcome was demonstrated in the HIV group when the CD4 
count was less than 200cells/mm3 in contrast to that which occurred when the CD4 
count was greater than 200cells/mm3. However, the survival difference was not 
statistically significant as the p value was 0.750.   
In the HIV positive group, DLBCL was diagnosed three times more frequently on 
biopsies of extranodal topographic sites than lymph node biopsies.  In contrast, in 
the HIV negative group, DLBCL was diagnosed in relatively equal proportion on 
biopsies of nodal and extranodal sites.  
In 2004, the South African National Antiretroviral Treatment Guidelines stipulated 
specific criteria for the initiation of antiviral therapy in patients infected with HIV. 
These criteria included CD4 <200 cells/mm3 irrespective of the WHO-defined 
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disease stage or WHO stage IV AIDS-defining illness (which included lymphoma) 
irrespective of the CD4 count.  An accompanying essential criterion was that of 
patient willingness and readiness to take antiviral therapy adherently.  99       
In 2010, the South African National guidelines were amended to include initiation of 
ART when CD4 counts less than 350cells/mm3 occurred in patients with TB and HIV 
co-infection and in pregnant women.  In addition, the criterion for the presence of 
drug-resistant tuberculosis (MDR/XDR), irrespective of the CD4 count, was included.  
100  During the period of this study, the 2004 national ART guidelines were in place.  
As such, all HIV positive patients in the study received HAART, either prior to the 
diagnosis of lymphoma or at the time of lymphoma diagnosis.  A statistically 
significant finding in this study was that the overall survival of patients with DLBCL 
and HIV infection was significantly poorer than that of patients with DLBCL in the 
absence of HIV infection (p value <0.001). This finding contrasts that of several 
studies in which higher remission and improved survival rates have been established 
in NHL occurring in HIV positive patients receiving HAART. 94, 96, 148, 149 
Factors contributing to the disparate survival outcome in our HIV positive group 
includes severe immunosuppression (mean CD4 121cells/mm3 ), delayed initiation of 
antiviral therapy until an advanced stage of HIV infection in combination with limiting 
issues such as ARV non-compliance and the dreaded possibility of ARV treatment 
failure.  During the course of the study, opportunistic diseases such as tuberculosis 
occurred in 11 HIV positive patients and Kaposi’s sarcoma was documented in 1 
additional patient.   However, deaths occurring in the HIV positive group were 
clinically and radiologically attributed to lymphoma rather than tuberculosis.  
 The researcher hopes that recent amendments to the national ARV policy will 
contribute to an improvement in the overall survival of HIV positive patients with 
NHL, such that future studies we will be able to demonstrate improved survival rates 
in parallel with those reported at present in Western countries.  For this to occur, 
additional amendments to the national ARV policy in terms of implementing a 
significantly lower threshold for initiating ARV treatment may be required to optimise 
antiviral treatment at less advanced stages of HIV infection.  
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Bcl-2 is known to be an inhibitor of apoptosis.  It is likely that the presence of high 
levels of Bcl-2 protein promotes survival of tumour cells by reducing apoptosis and 
conferring resistance to therapeutic agents. 150, 151, 152  Several studies (Hans et al. 
58, Muris et al. 66, Obermann et al. 81, Hermine et al. 82, Gascoyne et al. 83 and 
Barrans et al. 84) have showed that Bcl-2 expression is associated with poor 
prognosis.  In the present study, Bcl-2 expression occurring in non-germinal centre 
DLBCL was not associated with prognostic significance and no statistic significance 
was found when Bcl-2 expression was assessed by univariate analysis, independent 
of the IPI score, CD10, Bcl-6 and MUM1 expression.   
Interestingly, when the occurrence of Bcl-2 expression in germinal center-type 
DLBCL was assessed using the Hans algorithmic stratification, improved overall 
survival was conferred by the germinal center phenotype.  The accompanying 
statistically significant p value was 0.007.   This study hereby provides additional 
support of the previously established finding by Barrans et al. 84 in that the GC 
phenotype was associated with an improved survival in both Bcl-2 positive and 
negative groups. 78 
In addition, Muris et al. 66 found that Bcl-2- positive cases which concomitantly 
expressed CD10 were found to have significantly better outcome than CD10-
negative cases.  This finding suggested that Bcl-2 expression alone may be 
insufficient to fully inhibit chemotherapy-induced apoptosis. 
There is corroborative evidence supportive of the understanding that CD10- 
expressing lymphoid cells, both neoplastic and non-neoplastic, are inclined to 
become increasingly prone to apoptosis.  Often there is associated c-myc 
upregulation within these cells with resultant cellular induction into the cell cycle.    
This process creates the potential for improved response to apoptosis-inducing 
therapy in CD10-expressing DLBCL and may well account for a significant survival 
advantage.  67-71 
. 
Several researchers have reiterated the positive prognostic influence associated with 
Bcl-6 immunoexpression in DLBCL (Lossos et al. 64, Winter et al. 65, Amen at al. 63).  
In further support thereof, this study demonstrated that Bcl-6 expression in DLBCL 
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was associated with longer overall survival.  However, the survival advantage was 
not found to be statistically significant (p value 0.487). 
Hoffman et al. 49 established that CD138 expression was associated with poor 
overall survival in AIDS-related B-cell lymphomas. 52  In contrast, Tumwine et al. 62 
found that activated germinal center DLBCL, defined as those expressing CD10, Bcl-
6, MUM1 and CD138, was associated with superior survival outcome.  In the present 
study, statistic observation revealed that CD138 expression in >25% of tumour cells 
(score ≥2), occurred only in the HIV positive group and was associated with shorter 
survival time.  However, no statistical significance was evident (p 0.402).  Further 
investigation of the significance of CD138 expression in larger studies is required as 
expression thereof is likely to be associated with poorer prognosis in light of plasma 
cell and/or post-follicular differentiation (i.e. activated B cell phenotype).   
Plasmablastic lymphoma occurs predominantly in immunocompromised patients and 
is estimated to account for 2.6% of all AIDS- associated non-Hodgkin lymphomas. 
113, 116   PBL may also occur in HIV-negative patients as confirmed in rare case 
reports 119-121   PBL is known to be a very aggressive NHL with poor outcome as the 
estimated survival is usually less than one year. 15   The present study included 9 
cases of de novo PBL occurring in HIV positive patients.  Analysis of the age at 
presentation showed that HIV positive patients with PBL were significantly younger 
(greater than a decade) than those with DLBCL (HIV/PBL - mean age 36 years; 
HIV/DLBCL - mean age 48 years).  A difference of 18 years was found between the 
mean age at presentation of HIV positive patients with PBL and HIV negative 
patients with DLBCL.   
In this study the researcher established that patients with PBL had a significantly 
lower mean CD4 count (61cells/mm3) in contrast to the mean CD4 count of 
151cells/mm3 in patients with DLBCL.  The mean CD4 count in patients with PBL in 
our study is in-keeping with that quoted by Castillo et al. 153 (<200/mm3) and lower 
than the CD4 count of 300/mm3 reported in a case study by Flaitz et al.  153 154    
Two cases of PBL occurred in the oral cavity and seven were diagnosed at extra-oral 
and extranodal topographic sites.  While classic blast-like morphology was evident in 
the tumours occurring in the oral cavity, morphologic features of plasmacytic 
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differentiation, which at times appeared subtle, were evident in some PBL cases 
occurring in extra-oral sites.  All cases of PBL in our study lacked CD20 expression 
and 8/9 cases displayed MUM1 immuno-expression in 76-100% of tumour cells.  
The single case of PBL which lacked MUM1 expression occurred in an extra-oral 
location and displayed VS38C, CD138 and CD38 immunoexpression in 76-100% of 
tumour cells.  Interestingly, of all our PBL cases, the MUM1-negative case showed 
the highest level of EBV-LMP1 expression which involved 51-75% of tumour cells.  
Overall, EBV LMP1 immunoexpression was detected in 3/9 PBL cases.   
In keeping with the literature, the proliferation index in all our cases of PBL was high, 
ranging from 76 to >95%.  A statistically significant difference in survival was 
established in that the overall survival of patients with PBL was poorer than that of 
DLBCL (p value 0.002).  The mean survival of patients with PBL was found to be 16 
months from initial diagnosis. This mean value may over-score the true mean value 
for survival in this group as 4 of the patients in this group were lost to follow-up.  The 
scenario of “lost to follow-up” was a significant limiting factor in this group of patients.  
In the South African milieu, loss of follow up may be attributed to low socio-economic 
status resulting in frequent logistic and financial difficulties in accessing medical 
treatment, poor nutritional status, undiagnosed opportunistic diseases and the 
unfortunate reality of death occurring in non-hospitalised patients. 
 
11.  CONCLUSION 
This study confirms that diffuse large B cell lymphoma and plasmablastic lymphoma 
are high-grade tumours with significant potential for aggressive behaviour and poor 
outcome in the setting of profound immunosuppression due to HIV infection.  The 
HIV positive patients were found to be of strikingly younger age at presentation with 
greater likelihood of extranodal disease at diagnosis.  A statistically significant finding 
in this study was that the overall survival of patients with DLBCL and HIV infection 
was significantly poorer than that of patients with DLBCL in the absence of HIV 
infection (p value <0.001).  When Bcl-2 expression in germinal center-type DLBCL 
was assessed using the Hans algorithmic stratification, improved overall survival was 
conferred by the germinal center phenotype.  The accompanying statistically 
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significant p value was 0.007.  In addition, statistical observation revealed that 
CD138 expression in DLBCL involving >25% of tumour cells (score ≥2), occurred 
only in the HIV positive group and was associated with shorter survival time.  
However, no statistical significance was evident (p 0.402).  Further investigation of 
the prognostic significance of CD138 expression in DLBCL in larger studies is 
required as expression thereof is likely to be associated with poorer prognosis in light 
of plasma cell and/or post-follicular differentiation (i.e. activated B cell phenotype. 
This study established a statistically significant difference in survival regarding 
DLBCL and PBL in that the overall survival of patients with PBL was poorer than that 
of DLBCL.  Furthermore, this study showed that at the time of initial presentation of 
lymphoma, patients with PBL had a significantly lower mean CD4 count 
(61cells/mm3) in contrast to the mean CD4 count of 151cells/mm3 in patients with 
DLBCL.   
The recent amendment of the South African National Antiretroviral Treatment 
Guidelines has created the potential for improved survival in patients with AIDS-
related malignancies.  Further studies are required to assess the effect of these 
amendments in combination with the role o  targeted-immunotherapy on survival in 
patients with AIDS-related lymphomas.  In DLBCL specifically, the combined 
analysis of gene expression profiles by cDNA microarray and protein expression by 
immunohistochemistry will contribute to more accurate subclassification, hereby 
offering tremendous potential for prognostic stratification.  However, in many 
histopathology laboratories, routine cDNA microarray analysis of DLBCL may not be 
feasible due to constraints associated with cost, time and availability of interpretative 
skills.  This study has demonstrated that in the South African setting, the 
combination of clinical and biochemical prognostic parameters coupled with thorough 
morphologic assessment and immunohistochemical analysis of DLBCL and PBL has 
proven to yield prognostically useful information.  In future, this may facilitate the 
consideration of management stratification of HIV positive patients with DLBCL or 
PBL. 
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UNN ERSITY OF CAPE TOWN 
, 
02]une 2006 
REC REF: 209/2006 
Dr S Pather 
Anatomical Pathology 
Dear Dr Pather 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021) 406 6338 • Facsimile [021) 406 6411 
e-mail: preaward@curie.uct .. ac.za 
PRO]ECf TITLE: LARGE CELL LYMPHOMA: CORRELATION OF 
IMMUNODEFICIENCY VIRUS (HlV) STATUS AND PROGNOSIS 
HUMAN 
WITH 
DIFFERENTIATION PROFILES ASSESSED BY IMMUNOPHENOTYPING 
Thank you for submitting your study to the Research Ethics Committee for review. 
It is a pleasure to infann you that the E thics Committee has formally approved the above-mentioned study. 
Please ensure that any potentially identifying information is anonymised (ie. No personal identifying details are 
collected) or de-identified. 
Tbis serves to confirm that the University of Cape Town Research Ethics Committee complies to the Ethics 
Standards for Clinic.U Research with a new drug in patients, based on the Medical Research Council (MRC-
SA), Food and Drug Administration (FDA-USA), International Convention on 
HannorUsation Good Clinical Practice (ICH GCP) and Declaration ofHe1sinki guidelines. 
The Research Ethics Committee granting this approval is in compliance with the TCH Harmonised Tripartite 
Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) and FDA Code Federal 
Regulation Part 50, 56 and 312. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the REC. REF in all your correspondence. 
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Yours sincerely 
~~~ 
A/PROF. M. BLOCKMAN 
CHAIRPERSON. HSF HUMAN ETHICS 
lemjedi 
